{"name":"AbbVie","slug":"abbvie","ticker":"ABBV","exchange":"NYSE","domain":"abbvie.com","description":"AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.","hq":"North Chicago, IL","founded":2013,"employees":"57000","ceo":"Robert A. Michael","sector":"Big Pharma","stockPrice":210.03,"stockChange":3.66,"stockChangePercent":1.77,"marketCap":"$371.5B","metrics":{"revenue":61160000000,"revenueGrowth":10,"grossMargin":71.6,"rdSpend":0,"netIncome":4226000000,"cash":5256999936,"dividendYield":3.35,"peRatio":88.6,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"Abrilada","genericName":"Adalimumab-Afzb","slug":"abrilada","revenue":10191000000,"yoyGrowth":0,"percentOfTotal":29.2},{"name":"Skyrizi","genericName":"RISANKIZUMAB","slug":"risankizumab","revenue":8600000000,"yoyGrowth":0,"percentOfTotal":24.7},{"name":"Rinvoq","genericName":"upadacitinib","slug":"upadacitinib","revenue":5300000000,"yoyGrowth":0,"percentOfTotal":15.2},{"name":"Vraylar","genericName":"CARIPRAZINE","slug":"cariprazine","revenue":3267000000,"yoyGrowth":0,"percentOfTotal":9.4},{"name":"Imbruvica","genericName":"ibrutinib","slug":"ibrutinib","revenue":3200000000,"yoyGrowth":0,"percentOfTotal":9.2},{"name":"Venclexta","genericName":"venetoclax","slug":"venetoclax","revenue":2583000000,"yoyGrowth":0,"percentOfTotal":7.4},{"name":"Ubrelvy","genericName":"UBROGEPANT","slug":"ubrogepant","revenue":664000000,"yoyGrowth":0,"percentOfTotal":1.9},{"name":"Orilissa","genericName":"ELAGOLIX","slug":"elagolix","revenue":600000000,"yoyGrowth":0,"percentOfTotal":1.7},{"name":"Dalvance","genericName":"DALBAVANCIN","slug":"dalbavancin","revenue":260000000,"yoyGrowth":0,"percentOfTotal":0.7},{"name":"Qulipta","genericName":"ATOGEPANT","slug":"atogepant","revenue":201000000,"yoyGrowth":0,"percentOfTotal":0.6}],"timeline":[{"date":"1944-01-01","label":"Dicuman first approved","drug":"Dicuman","drugSlug":"dicoumarol","type":"approval","sentiment":"positive"},{"date":"1954-01-01","label":"Bromanautine first approved","drug":"Bromanautine","drugSlug":"bromazine","type":"approval","sentiment":"positive"},{"date":"1959-01-01","label":"Akineton first approved","drug":"Akineton","drugSlug":"biperiden","type":"approval","sentiment":"positive"},{"date":"1961-01-01","label":"Alvinol first approved","drug":"Alvinol","drugSlug":"ethchlorvynol","type":"approval","sentiment":"positive"},{"date":"1967-01-01","label":"Choloxin first approved","drug":"Choloxin","drugSlug":"dextrothyroxine","type":"approval","sentiment":"positive"},{"date":"1969-01-01","label":"Medrifar first approved","drug":"Medrifar","drugSlug":"medrysone","type":"approval","sentiment":"positive"},{"date":"1972-01-01","label":"Fml first approved","drug":"Fml","drugSlug":"fluorometholone","type":"approval","sentiment":"positive"},{"date":"1974-01-01","label":"Aldapsone first approved","drug":"Aldapsone","drugSlug":"aldesulfone","type":"approval","sentiment":"positive"},{"date":"1980-01-01","label":"Dipivefrin first approved","drug":"Dipivefrin","drugSlug":"dipivefrine","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Betagan first approved","drug":"Betagan","drugSlug":"levobunolol","type":"approval","sentiment":"positive"},{"date":"1987-01-01","label":"Actigall first approved","drug":"Actigall","drugSlug":"ursodiol","type":"approval","sentiment":"positive"},{"date":"1991-01-01","label":"Survanta first approved","drug":"Survanta","drugSlug":"beractant","type":"approval","sentiment":"positive"},{"date":"1992-01-01","label":"Alocril first approved","drug":"Alocril","drugSlug":"nedocromil","type":"approval","sentiment":"positive"},{"date":"1992-01-01","label":"Mivacron first approved","drug":"Mivacron","drugSlug":"mivacurium","type":"approval","sentiment":"positive"},{"date":"1995-01-01","label":"Nimbex first approved","drug":"Nimbex","drugSlug":"cisatracurium-besylate","type":"approval","sentiment":"positive"},{"date":"1995-01-01","label":"Nimbex first approved","drug":"Nimbex","drugSlug":"cisatracurium","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Norvir first approved","drug":"Norvir","drugSlug":"ritonavir","type":"approval","sentiment":"positive"},{"date":"1997-01-01","label":"Teveten first approved","drug":"Teveten","drugSlug":"eprosartan","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Zemplar first approved","drug":"Zemplar","drugSlug":"paricalcitol","type":"approval","sentiment":"positive"},{"date":"1998-01-01","label":"Celexa first approved","drug":"Celexa","drugSlug":"citalopram","type":"approval","sentiment":"positive"},{"date":"2000-01-01","label":"Kaletra first approved","drug":"Kaletra","drugSlug":"lopinavir","type":"approval","sentiment":"positive"},{"date":"2002-01-01","label":"Abrilada first approved","drug":"Abrilada","drugSlug":"abrilada","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Elestat first approved","drug":"Elestat","drugSlug":"epinastine","type":"approval","sentiment":"positive"},{"date":"2003-01-01","label":"Namenda first approved","drug":"Namenda","drugSlug":"memantine","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Campral first approved","drug":"Campral","drugSlug":"acamprosate","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Sanctura first approved","drug":"Sanctura","drugSlug":"trospium","type":"approval","sentiment":"positive"},{"date":"2004-01-01","label":"Enablex first approved","drug":"Enablex","drugSlug":"darifenacin","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Rapaflo first approved","drug":"Rapaflo","drugSlug":"silodosin","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Trilipix first approved","drug":"Trilipix","drugSlug":"choline-fenofibrate","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Lastacaft first approved","drug":"Lastacaft","drugSlug":"alcaftadine","type":"approval","sentiment":"positive"},{"date":"2010-01-01","label":"Teflaro first approved","drug":"Teflaro","drugSlug":"ceftaroline-fosamil","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Ceftaroline Fosamil first approved","drug":"Ceftaroline Fosamil","drugSlug":"ceftaroline","type":"approval","sentiment":"positive"},{"date":"2012-01-01","label":"Linzess first approved","drug":"Linzess","drugSlug":"linaclotide","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Imbruvica first approved","drug":"Imbruvica","drugSlug":"ibrutinib","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Fetzima first approved","drug":"Fetzima","drugSlug":"levomilnacipran","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Venclexta first approved","drug":"Venclexta","drugSlug":"venetoclax","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Dalvance first approved","drug":"Dalvance","drugSlug":"dalbavancin","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Viekira Pak (Copackaged) first approved","drug":"Viekira Pak (Copackaged)","drugSlug":"dasabuvir","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Vraylar first approved","drug":"Vraylar","drugSlug":"cariprazine","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Kybella first approved","drug":"Kybella","drugSlug":"deoxycholic-acid","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Viberzi first approved","drug":"Viberzi","drugSlug":"eluxadoline","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Mavyret first approved","drug":"Mavyret","drugSlug":"glecaprevir","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Orilissa first approved","drug":"Orilissa","drugSlug":"elagolix","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Skyrizi first approved","drug":"Skyrizi","drugSlug":"risankizumab","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Rinvoq first approved","drug":"Rinvoq","drugSlug":"upadacitinib","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Ubrelvy first approved","drug":"Ubrelvy","drugSlug":"ubrogepant","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Qulipta first approved","drug":"Qulipta","drugSlug":"atogepant","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Emrelis first approved","drug":"Emrelis","drugSlug":"telisotuzumab","type":"approval","sentiment":"positive"},{"date":"2026-06-01","label":"Skyrizi PHASE3 readout","drug":"Skyrizi","drugSlug":"risankizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-08-01","label":"Emrelis PHASE2 readout","drug":"Emrelis","drugSlug":"telisotuzumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-09-28","label":"Skyrizi PHASE3 readout","drug":"Skyrizi","drugSlug":"risankizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-09","label":"Imbruvica PHASE3 readout","drug":"Imbruvica","drugSlug":"ibrutinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-28","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-28","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2027-06-28","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-26","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-03","label":"Imbruvica patent expiry (Method of Use)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-03","label":"Imbruvica patent expiry (Method of Use)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-06-03","label":"Imbruvica patent expiry (Method of Use)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2031-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-06-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-06-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-06-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-06-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-08-18","label":"Imbruvica patent expiry (Method of Use)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2033-12-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2034-02-18","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2035-04-24","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2035-04-24","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-03-03","label":"Imbruvica patent expiry (Formulation)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-09-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-09-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-09-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-09-03","label":"Imbruvica patent expiry (Compound)","drug":"Imbruvica","drugSlug":"ibrutinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2036-10-17","label":"Rinvoq patent expiry (Formulation)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2038-03-09","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2038-03-09","label":"Rinvoq patent expiry (Method of Use)","drug":"Rinvoq","drugSlug":"upadacitinib","type":"patent_expiry","sentiment":"negative"},{"date":"2023-06-01","label":"Humira patent cliff ($19.8B at risk)","drug":"Humira","type":"patent_expiry","sentiment":"negative"},{"date":"2034-06-01","label":"Rinvoq patent cliff ($1.4B at risk)","drug":"Rinvoq","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":24091000000,"percentOfTotal":69.1,"drugCount":17,"colorKey":"oncology","drugs":[{"name":"Abrilada","genericName":"Adalimumab-Afzb","slug":"abrilada","indication":"Ankylosing spondylitis","status":"marketed","revenue":10191000000},{"name":"Skyrizi","genericName":"RISANKIZUMAB","slug":"risankizumab","indication":"Crohn's disease","status":"marketed","revenue":8600000000},{"name":"Rinvoq","genericName":"upadacitinib","slug":"upadacitinib","indication":"Rheumatoid Arthritis","status":"marketed","revenue":5300000000},{"name":"Humira","genericName":"ADALIMUMAB","slug":"adalimumab","indication":"Ankylosing spondylitis","status":"marketed"},{"name":"Norvir","genericName":"ritonavir","slug":"ritonavir","indication":"COVID-19","status":"marketed"},{"name":"Corticosteroid (CS)","genericName":"Corticosteroid (CS)","slug":"corticosteroid-cs","indication":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)","status":"marketed"},{"name":"ABT-494","genericName":"ABT-494","slug":"abt-494","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"Adalimumab, current formulation","genericName":"Adalimumab, current formulation","slug":"adalimumab-current-formulation","indication":"Rheumatoid Arthritis","status":"phase_2"},{"name":"Adalimumab, new formulation","genericName":"Adalimumab, new formulation","slug":"adalimumab-new-formulation","indication":"Rheumatoid arthritis","status":"phase_2"},{"name":"Open-label Adalimumab","genericName":"Open-label Adalimumab","slug":"open-label-adalimumab","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Placebo Upadacitinib","genericName":"Placebo Upadacitinib","slug":"placebo-upadacitinib","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Placebo for Risankizumab SC","genericName":"Placebo for Risankizumab SC","slug":"placebo-for-risankizumab-sc","indication":"Control arm in risankizumab phase 3 trials (likely psoriasis, Crohn's disease, or ulcerative colitis based on risankizumab's development program)","status":"phase_3"},{"name":"Placebo for Upadacitinib","genericName":"Placebo for Upadacitinib","slug":"placebo-for-upadacitinib","indication":"Control arm in Phase 3 clinical trials for upadacitinib indications (e.g., rheumatoid arthritis, atopic dermatitis, ulcerative colitis)","status":"phase_3"},{"name":"Topical corticosteroids (TCS)","genericName":"Topical corticosteroids (TCS)","slug":"topical-corticosteroids-tcs","indication":"Inflammatory skin conditions including atopic dermatitis, psoriasis, eczema, and contact dermatitis","status":"phase_3"},{"name":"Upadacitinib (ABT-494)","genericName":"Upadacitinib (ABT-494)","slug":"upadacitinib-abt-494","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"risankizumab IV","genericName":"risankizumab IV","slug":"risankizumab-iv","indication":"Moderate to severe plaque psoriasis","status":"phase_3"},{"name":"risankizumab SC","genericName":"risankizumab SC","slug":"risankizumab-sc","indication":"Moderate to severe plaque psoriasis","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":5783000000,"percentOfTotal":16.6,"drugCount":20,"colorKey":"cardiovascular","drugs":[{"name":"Imbruvica","genericName":"ibrutinib","slug":"ibrutinib","indication":"Chronic graft-versus-host disease","status":"marketed","revenue":3200000000},{"name":"Venclexta","genericName":"venetoclax","slug":"venetoclax","indication":"Acute myeloid leukemia, disease","status":"marketed","revenue":2583000000},{"name":"ABBV-444","genericName":"ABBV-444","slug":"abbv-444","indication":"Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer","status":"phase_3"},{"name":"ABBV-932","genericName":"ABBV-932","slug":"abbv-932","indication":"Solid tumors (specific indications under investigation in phase 2)","status":"phase_2"},{"name":"Emrelis","genericName":"TELISOTUZUMAB","slug":"telisotuzumab","indication":"non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","status":"marketed"},{"name":"ABBV-453","genericName":"ABBV-453","slug":"abbv-453","indication":"Non-Hodgkin lymphoma","status":"phase_1"},{"name":"ABBV-668","genericName":"ABBV-668","slug":"abbv-668","indication":"Relapsed or refractory mantle cell lymphoma","status":"phase_2"},{"name":"ABBV-706","genericName":"ABBV-706","slug":"abbv-706","indication":"Advanced solid tumors (in combination with checkpoint inhibitors)","status":"phase_3"},{"name":"ABT-348 and azacitidine","genericName":"ABT-348 and azacitidine","slug":"abt-348-and-azacitidine","indication":"Acute myeloid leukemia","status":"phase_1"},{"name":"ABT-348 and docetaxel","genericName":"ABT-348 and docetaxel","slug":"abt-348-and-docetaxel","indication":"Non-small cell lung cancer","status":"phase_1"},{"name":"ABT-712","genericName":"ABT-712","slug":"abt-712","indication":"Lung cancer with FGFR1 alterations","status":"phase_3"},{"name":"ABT-888","genericName":"ABT-888","slug":"abt-888","indication":"Metastatic breast cancer, triple-negative breast cancer, ovarian cancer","status":"phase_2"},{"name":"Leuprolide Acetate (LA)","genericName":"Leuprolide Acetate (LA)","slug":"leuprolide-acetate-la","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"Leuprolide Acetate 3 Month Depot","genericName":"Leuprolide Acetate 3 Month Depot","slug":"leuprolide-acetate-3-month-depot","indication":"Advanced prostate cancer","status":"phase_3"},{"name":"Mirvetuximab soravtansine plus Bevacizumab","genericName":"Mirvetuximab soravtansine plus Bevacizumab","slug":"mirvetuximab-soravtansine-plus-bevacizumab","indication":"Platinum-resistant ovarian cancer (folate receptor alpha positive)","status":"phase_3"},{"name":"Osimertinib (Osi)","genericName":"Osimertinib (Osi)","slug":"osimertinib-osi","indication":"Metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations (first-line)","status":"marketed"},{"name":"Placebo Methotrexate","genericName":"Placebo Methotrexate","slug":"placebo-methotrexate","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Placebo for Navitoclax","genericName":"Placebo for Navitoclax","slug":"placebo-for-navitoclax","indication":"Chronic lymphocytic leukemia (CLL)","status":"phase_3"},{"name":"Placebo to veliparib","genericName":"Placebo to veliparib","slug":"placebo-to-veliparib","indication":"Metastatic breast cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"modified FOLFIRINOX","genericName":"modified FOLFIRINOX","slug":"modified-folfirinox","indication":"Metastatic pancreatic cancer","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":4132000000,"percentOfTotal":11.9,"drugCount":27,"colorKey":"immunology","drugs":[{"name":"Vraylar","genericName":"CARIPRAZINE","slug":"cariprazine","indication":"Bipolar affective disorder, current episode manic","status":"marketed","revenue":3267000000},{"name":"Ubrelvy","genericName":"UBROGEPANT","slug":"ubrogepant","indication":"Migraine","status":"marketed","revenue":664000000},{"name":"Qulipta","genericName":"ATOGEPANT","slug":"atogepant","indication":"Preventive treatment of migraine","status":"marketed","revenue":201000000},{"name":"Nimbex","genericName":"Cisatracurium Besylate","slug":"cisatracurium-besylate","indication":"Tracheal intubation in adults","status":"marketed"},{"name":"ABBV-CLS-628","genericName":"ABBV-CLS-628","slug":"abbv-cls-628","indication":"Relapsing multiple sclerosis","status":"phase_2"},{"name":"ABT-894","genericName":"ABT-894","slug":"abt-894","indication":"Relapsing multiple sclerosis","status":"phase_2"},{"name":"FOSCARBIDOPA","genericName":"FOSCARBIDOPA","slug":"foscarbidopa","indication":"Parkinson's disease","status":"marketed"},{"name":"Metabarbital","genericName":"METHARBITAL","slug":"metharbital","indication":"Epilepsy","status":"marketed"},{"name":"Phenurone","genericName":"PHENACEMIDE","slug":"phenacemide","indication":"Epilepsy","status":"marketed"},{"name":"Viibryd","genericName":"vilazodone","slug":"vilazodone","indication":"Major depressive disorder","status":"marketed"},{"name":"ABBV-552","genericName":"ABBV-552","slug":"abbv-552","indication":"Moderate to severe multiple sclerosis","status":"phase_2"},{"name":"AGN-151607","genericName":"AGN-151607","slug":"agn-151607","indication":"Relapsing forms of multiple sclerosis","status":"phase_2"},{"name":"Akineton","genericName":"BIPERIDEN","slug":"biperiden","indication":"Arteriosclerotic Parkinsonism","status":"marketed"},{"name":"BOTOX®/VISTABEL®","genericName":"BOTOX®/VISTABEL®","slug":"botox-vistabel","indication":"Moderate to severe glabellar lines (frown lines)","status":"marketed"},{"name":"Cariprazine Flexible Dose","genericName":"Cariprazine Flexible Dose","slug":"cariprazine-flexible-dose","indication":"Schizophrenia","status":"phase_3"},{"name":"Celexa","genericName":"CITALOPRAM","slug":"citalopram","indication":"Depressive disorder","status":"marketed"},{"name":"FOSLEVODOPA","genericName":"FOSLEVODOPA","slug":"foslevodopa","indication":"Motor fluctuations in advanced Parkinson’s disease","status":"marketed"},{"name":"Fetzima","genericName":"LEVOMILNACIPRAN","slug":"levomilnacipran","indication":"Major depressive disorder","status":"marketed"},{"name":"Levodopa-carbidopa intestinal gel","genericName":"Levodopa-carbidopa intestinal gel","slug":"levodopa-carbidopa-intestinal-gel","indication":"Advanced Parkinson's disease with motor fluctuations inadequately controlled by oral levodopa-carbidopa","status":"phase_3"},{"name":"Levodopa/Carbidopa (LD/CD)","genericName":"Levodopa/Carbidopa (LD/CD)","slug":"levodopa-carbidopa-ld-cd","indication":"Parkinson's disease","status":"phase_3"},{"name":"Mivacron","genericName":"MIVACURIUM","slug":"mivacurium","indication":"General anesthesia","status":"marketed"},{"name":"Namenda","genericName":"MEMANTINE","slug":"memantine","indication":"Moderate to Severe Alzheimer's Type Dementia","status":"marketed"},{"name":"Nimbex","genericName":"CISATRACURIUM","slug":"cisatracurium","indication":"General anesthesia","status":"marketed"},{"name":"Optimized antiparkinsonian treatment","genericName":"Optimized antiparkinsonian treatment","slug":"optimized-antiparkinsonian-treatment","indication":"Parkinson's disease","status":"phase_3"},{"name":"Placebo for Atogepant","genericName":"Placebo for Atogepant","slug":"placebo-for-atogepant","indication":"Control arm in atogepant clinical trials for migraine prevention","status":"phase_3"},{"name":"Placebo for Ubrogepant","genericName":"Placebo for Ubrogepant","slug":"placebo-for-ubrogepant","indication":"Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment)","status":"phase_3"},{"name":"Placebo-Matching Atogepant","genericName":"Placebo-Matching Atogepant","slug":"placebo-matching-atogepant","indication":"Migraine prevention in adults","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":600000000,"percentOfTotal":1.7,"drugCount":106,"colorKey":"neuroscience","drugs":[{"name":"Orilissa","genericName":"ELAGOLIX","slug":"elagolix","indication":"Endometriosis","status":"marketed","revenue":600000000},{"name":"Actigall","genericName":"URSODIOL","slug":"ursodiol","indication":"Calculus in biliary tract","status":"marketed"},{"name":"Ravaglimab","genericName":"Ravaglimab","slug":"ravaglimab","indication":"Other","status":"discontinued"},{"name":"ABBV-011","genericName":"ABBV-011","slug":"abbv-011","indication":"Other","status":"phase_1"},{"name":"ABBV-1042","genericName":"ABBV-1042","slug":"abbv-1042","indication":"Other","status":"phase_1"},{"name":"ABBV-142","genericName":"ABBV-142","slug":"abbv-142","indication":"Other","status":"phase_2"},{"name":"ABBV-157","genericName":"ABBV-157","slug":"abbv-157","indication":"Other","status":"phase_1"},{"name":"ABBV-181","genericName":"ABBV-181","slug":"abbv-181","indication":"Other","status":"phase_1"},{"name":"ABBV-243","genericName":"ABBV-243","slug":"abbv-243","indication":"Other","status":"phase_1"},{"name":"ABBV-277","genericName":"ABBV-277","slug":"abbv-277","indication":"Other","status":"phase_1"},{"name":"ABBV-291","genericName":"ABBV-291","slug":"abbv-291","indication":"Other","status":"phase_1"},{"name":"ABBV-295","genericName":"ABBV-295","slug":"abbv-295","indication":"Other","status":"phase_1"},{"name":"ABBV-3067","genericName":"ABBV-3067","slug":"abbv-3067","indication":"Other","status":"phase_2"},{"name":"ABBV-319","genericName":"ABBV-319","slug":"abbv-319","indication":"Other","status":"phase_1"},{"name":"ABBV-324","genericName":"ABBV-324","slug":"abbv-324","indication":"Other","status":"phase_1"},{"name":"ABBV-368","genericName":"ABBV-368","slug":"abbv-368","indication":"Other","status":"phase_1"},{"name":"ABBV-400","genericName":"ABBV-400","slug":"abbv-400","indication":"Other","status":"phase_2"},{"name":"ABBV-428","genericName":"ABBV-428","slug":"abbv-428","indication":"Other","status":"phase_1"},{"name":"ABBV-438","genericName":"ABBV-438","slug":"abbv-438","indication":"Other","status":"phase_1"},{"name":"ABBV-47D11","genericName":"ABBV-47D11","slug":"abbv-47d11","indication":"Other","status":"phase_1"},{"name":"ABBV-621","genericName":"ABBV-621","slug":"abbv-621","indication":"Other","status":"phase_1"},{"name":"ABBV-637","genericName":"ABBV-637","slug":"abbv-637","indication":"Other","status":"phase_1"},{"name":"ABBV-6628","genericName":"ABBV-6628","slug":"abbv-6628","indication":"Other","status":"phase_1"},{"name":"ABBV-701","genericName":"ABBV-701","slug":"abbv-701","indication":"Other","status":"phase_1"},{"name":"ABBV-711","genericName":"ABBV-711","slug":"abbv-711","indication":"Other","status":"phase_1"},{"name":"ABBV-901","genericName":"ABBV-901","slug":"abbv-901","indication":"Other","status":"phase_1"},{"name":"ABBV-903 Tablet Form 2","genericName":"ABBV-903 Tablet Form 2","slug":"abbv-903-tablet-form-2","indication":"Other","status":"phase_1"},{"name":"ABT-414","genericName":"ABT-414","slug":"abt-414","indication":"Other","status":"phase_2"},{"name":"ABT-530","genericName":"ABT-530","slug":"abt-530","indication":"Inflammatory conditions (Phase 2 development)","status":"phase_2"},{"name":"Alvinol","genericName":"ETHCHLORVYNOL","slug":"ethchlorvynol","indication":"Insomnia","status":"marketed"},{"name":"Betaprone","genericName":"PROPIOLACTONE","slug":"propiolactone","indication":"Antiseptic preparation","status":"marketed"},{"name":"Campral","genericName":"ACAMPROSATE","slug":"acamprosate","indication":"Alcoholism","status":"marketed"},{"name":"Lastacaft","genericName":"ALCAFTADINE","slug":"alcaftadine","indication":"Allergic conjunctivitis","status":"marketed"},{"name":"Medrifar","genericName":"MEDRYSONE","slug":"medrysone","indication":"Allergic conjunctivitis","status":"marketed"},{"name":"Placebo for E2/NETA","genericName":"Placebo for E2/NETA","slug":"placebo-for-e2-neta","indication":"Control arm in phase 3 trial for estradiol/norethindrone acetate (E2/NETA) hormone replacement therapy","status":"phase_3"},{"name":"Sanctura","genericName":"TROSPIUM","slug":"trospium","indication":"Bladder muscle dysfunction - overactive","status":"marketed"},{"name":"Zemplar","genericName":"PARICALCITOL","slug":"paricalcitol","indication":"Hyperparathyroidism Secondary to Chronic Renal Failure","status":"marketed"},{"name":"ABBV-066","genericName":"ABBV-066","slug":"abbv-066","indication":"Other","status":"phase_1"},{"name":"ABBV-075","genericName":"ABBV-075","slug":"abbv-075","indication":"Other","status":"phase_1"},{"name":"ABBV-085","genericName":"ABBV-085","slug":"abbv-085","indication":"Other","status":"phase_1"},{"name":"ABBV-101","genericName":"ABBV-101","slug":"abbv-101","indication":"Other","status":"phase_1"},{"name":"ABBV-1354","genericName":"ABBV-1354","slug":"abbv-1354","indication":"Other","status":"phase_1"},{"name":"ABBV-141","genericName":"ABBV-141","slug":"abbv-141","indication":"Other","status":"phase_1"},{"name":"ABBV-154 Dose Formulation A","genericName":"ABBV-154 Dose Formulation A","slug":"abbv-154-dose-formulation-a","indication":"Other","status":"phase_1"},{"name":"ABBV-154 Dose Formulation B","genericName":"ABBV-154 Dose Formulation B","slug":"abbv-154-dose-formulation-b","indication":"Other","status":"phase_1"},{"name":"ABBV-155","genericName":"ABBV-155","slug":"abbv-155","indication":"Other","status":"phase_1"},{"name":"ABBV-2222","genericName":"ABBV-2222","slug":"abbv-2222","indication":"Other","status":"phase_2"},{"name":"ABBV-2B04","genericName":"ABBV-2B04","slug":"abbv-2b04","indication":"Other","status":"phase_1"},{"name":"ABBV-321","genericName":"ABBV-321","slug":"abbv-321","indication":"Other","status":"phase_1"},{"name":"ABBV-525","genericName":"ABBV-525","slug":"abbv-525","indication":"Other","status":"phase_1"},{"name":"ABBV-547","genericName":"ABBV-547","slug":"abbv-547","indication":"Other","status":"phase_1"},{"name":"ABBV-668 IR","genericName":"ABBV-668 IR","slug":"abbv-668-ir","indication":"Other","status":"phase_1"},{"name":"ABBV-722","genericName":"ABBV-722","slug":"abbv-722","indication":"Other","status":"phase_1"},{"name":"ABBV-8736","genericName":"ABBV-8736","slug":"abbv-8736","indication":"Other","status":"phase_2"},{"name":"ABBV-903 Tablet Form 1","genericName":"ABBV-903 Tablet Form 1","slug":"abbv-903-tablet-form-1","indication":"Other","status":"phase_1"},{"name":"ABBV-916","genericName":"ABBV-916","slug":"abbv-916","indication":"Other","status":"phase_2"},{"name":"ABBV-927","genericName":"ABBV-927","slug":"abbv-927","indication":"Other","status":"phase_1"},{"name":"ABBV-969","genericName":"ABBV-969","slug":"abbv-969","indication":"Other","status":"phase_1"},{"name":"ABBV-CLS-579","genericName":"ABBV-CLS-579","slug":"abbv-cls-579","indication":"Other","status":"phase_1"},{"name":"ABBV-CLS-616","genericName":"ABBV-CLS-616","slug":"abbv-cls-616","indication":"Other","status":"phase_1"},{"name":"ABT-288 Low Dose","genericName":"ABT-288 Low Dose","slug":"abt-288-low-dose","indication":"Other","status":"phase_2"},{"name":"ABT-308","genericName":"ABT-308","slug":"abt-308","indication":"Other","status":"phase_1"},{"name":"ABT-348","genericName":"ABT-348","slug":"abt-348","indication":"Other","status":"phase_1"},{"name":"ABT-348 and carboplatin","genericName":"ABT-348 and carboplatin","slug":"abt-348-and-carboplatin","indication":"Other","status":"phase_1"},{"name":"ABT-354","genericName":"ABT-354","slug":"abt-354","indication":"Other","status":"phase_1"},{"name":"ABT-652 NSAID","genericName":"ABT-652 NSAID","slug":"abt-652-nsaid","indication":"Other","status":"phase_2"},{"name":"ABT-700","genericName":"ABT-700","slug":"abt-700","indication":"Other","status":"phase_1"},{"name":"ABT-767","genericName":"ABT-767","slug":"abt-767","indication":"Other","status":"phase_1"},{"name":"ABT-806","genericName":"ABT-806","slug":"abt-806","indication":"Other","status":"phase_2"},{"name":"ABT-981","genericName":"ABT-981","slug":"abt-981","indication":"Other","status":"phase_2"},{"name":"AGN-151586","genericName":"AGN-151586","slug":"agn-151586","indication":"Muscle wasting / sarcopenia","status":"phase_3"},{"name":"AGN-151597","genericName":"AGN-151597","slug":"agn-151597","indication":"Other","status":"phase_1"},{"name":"AGN-151607-DP","genericName":"AGN-151607-DP","slug":"agn-151607-dp","indication":"Other","status":"phase_2"},{"name":"AGN-193408 SR","genericName":"AGN-193408 SR","slug":"agn-193408-sr","indication":"Other","status":"phase_1"},{"name":"AGN-231868","genericName":"AGN-231868","slug":"agn-231868","indication":"Other","status":"phase_1"},{"name":"ALIA-1758","genericName":"ALIA-1758","slug":"alia-1758","indication":"Other","status":"phase_1"},{"name":"Aldapsone","genericName":"aldesulfone","slug":"aldesulfone","indication":"Other","status":"marketed"},{"name":"Armour Thyroid","genericName":"Armour Thyroid","slug":"armour-thyroid","indication":"Hypothyroidism (primary, secondary, and tertiary)","status":"marketed"},{"name":"Bromanautine","genericName":"bromazine","slug":"bromazine","indication":"Common cold","status":"marketed"},{"name":"Budiglimab","genericName":"Budiglimab","slug":"budiglimab","indication":"Other","status":"discontinued"},{"name":"CREON","genericName":"LIPASE","slug":"lipase","indication":"Other","status":"marketed"},{"name":"CREON","genericName":"PROTEASE)","slug":"protease","indication":"Other","status":"marketed"},{"name":"Elestat","genericName":"EPINASTINE","slug":"epinastine","indication":"Prevention of itching due to allergic conjunctivitis","status":"marketed"},{"name":"Enablex","genericName":"DARIFENACIN","slug":"darifenacin","indication":"Bladder muscle dysfunction - overactive","status":"marketed"},{"name":"Fml","genericName":"FLUOROMETHOLONE","slug":"fluorometholone","indication":"Steroid-responsive ocular inflammation","status":"marketed"},{"name":"Fumaderm","genericName":"Fumaderm","slug":"fumaderm","indication":"Other","status":"phase_3"},{"name":"HEXOCYCLIUM","genericName":"HEXOCYCLIUM","slug":"hexocyclium","indication":"Other","status":"marketed"},{"name":"Kybella","genericName":"DEOXYCHOLIC ACID","slug":"deoxycholic-acid","indication":"Excess subcutaneous fat","status":"marketed"},{"name":"Linzess","genericName":"LINACLOTIDE","slug":"linaclotide","indication":"Chronic idiopathic constipation","status":"marketed"},{"name":"Lubricating Eye Drops","genericName":"Lubricating Eye Drops","slug":"lubricating-eye-drops","indication":"Other","status":"marketed"},{"name":"Matching Placebo for Upadacitinib","genericName":"Matching Placebo for Upadacitinib","slug":"matching-placebo-for-upadacitinib","indication":"Other","status":"phase_3"},{"name":"PERTZYE","genericName":"PERTZYE","slug":"pertzye","indication":"Other","status":"marketed"},{"name":"Placebo (PBO) oral capsules","genericName":"Placebo (PBO) oral capsules","slug":"placebo-pbo-oral-capsules","indication":"Control arm in phase 3 clinical trials (non-therapeutic use)","status":"phase_3"},{"name":"Placebo for ABBV-951","genericName":"Placebo for ABBV-951","slug":"placebo-for-abbv-951","indication":"Other","status":"phase_3"},{"name":"Placebo for ABT-333","genericName":"Placebo for ABT-333","slug":"placebo-for-abt-333","indication":"Other","status":"phase_3"},{"name":"Placebo for ABT-414","genericName":"Placebo for ABT-414","slug":"placebo-for-abt-414","indication":"Other","status":"phase_3"},{"name":"Placebo for ABT-493/ABT-530","genericName":"Placebo for ABT-493/ABT-530","slug":"placebo-for-abt-493-abt-530","indication":"Other","status":"phase_3"},{"name":"Placebo for Elagolix","genericName":"Placebo for Elagolix","slug":"placebo-for-elagolix","indication":"Control arm in Phase 3 clinical trials for Elagolix","status":"phase_3"},{"name":"Placebo for Estradiol/Norethindrone Acetate","genericName":"Placebo for Estradiol/Norethindrone Acetate","slug":"placebo-for-estradiol-norethindrone-acetate","indication":"Control arm in clinical trials of Estradiol/Norethindrone Acetate for menopausal symptom management","status":"phase_3"},{"name":"Placebo for Linaclotide","genericName":"Placebo for Linaclotide","slug":"placebo-for-linaclotide","indication":"Control arm in linaclotide clinical trials (Phase 3)","status":"phase_3"},{"name":"Placebo for Topiramate","genericName":"Placebo for Topiramate","slug":"placebo-for-topiramate","indication":"Control for Topiramate efficacy in clinical trials","status":"phase_3"},{"name":"Placebo for venetoclax","genericName":"Placebo for venetoclax","slug":"placebo-for-venetoclax","indication":"Control arm in phase 3 clinical trial for venetoclax","status":"phase_3"},{"name":"Placebo to upadacitinib","genericName":"Placebo to upadacitinib","slug":"placebo-to-upadacitinib","indication":"Other","status":"phase_3"},{"name":"Rapaflo","genericName":"SILODOSIN","slug":"silodosin","indication":"Treatment of BPH","status":"marketed"},{"name":"placebo for risankizumab","genericName":"placebo for risankizumab","slug":"placebo-for-risankizumab","indication":"Other","status":"marketed"},{"name":"placebo for rizankizumab","genericName":"placebo for rizankizumab","slug":"placebo-for-rizankizumab","indication":"Other","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":260000000,"percentOfTotal":0.7,"drugCount":20,"colorKey":"infectious","drugs":[{"name":"Dalvance","genericName":"DALBAVANCIN","slug":"dalbavancin","indication":"Bacterial infection of skin","status":"marketed","revenue":260000000},{"name":"ABT-333","genericName":"ABT-333","slug":"abt-333","indication":"Chronic hepatitis C virus infection (genotype 1)","status":"phase_3"},{"name":"Ceftaroline Fosamil","genericName":"CEFTAROLINE","slug":"ceftaroline","indication":"Acute bacterial skin and skin structure infections","status":"marketed"},{"name":"ABT-267","genericName":"ABT-267","slug":"abt-267","indication":"Diabetic kidney disease","status":"phase_3"},{"name":"ABT-450","genericName":"ABT-450","slug":"abt-450","indication":"Chronic hepatitis C virus (HCV) infection","status":"phase_2"},{"name":"ABT-450/r/ABT-267","genericName":"ABT-450/r/ABT-267","slug":"abt-450-r-abt-267","indication":"Chronic hepatitis C virus infection (genotype 1)","status":"phase_3"},{"name":"ABT-450/r/ABT-267, ABT-333","genericName":"ABT-450/r/ABT-267, ABT-333","slug":"abt-450-r-abt-267-abt-333","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1","status":"phase_3"},{"name":"ABT-450/ritonavir","genericName":"ABT-450/ritonavir","slug":"abt-450-ritonavir","indication":"Chronic hepatitis C virus infection (genotype 1 and 4)","status":"phase_3"},{"name":"ABT-493","genericName":"ABT-493","slug":"abt-493","indication":"Chronic hepatitis C virus infection","status":"phase_2"},{"name":"ABT-493 coformulated with ABT-530","genericName":"ABT-493 coformulated with ABT-530","slug":"abt-493-coformulated-with-abt-530","indication":"Chronic hepatitis C virus (HCV) infection, genotype 1-6","status":"phase_3"},{"name":"ABT-493/ABT-530","genericName":"ABT-493/ABT-530","slug":"abt-493-abt-530","indication":"Chronic hepatitis C virus infection (genotypes 1-6)","status":"phase_3"},{"name":"Dasabuvir mini tablet","genericName":"Dasabuvir mini tablet","slug":"dasabuvir-mini-tablet","indication":"Chronic hepatitis C","status":"phase_2"},{"name":"Kaletra","genericName":"LOPINAVIR","slug":"lopinavir","indication":"HIV-1 Infection Treatment","status":"marketed"},{"name":"Mavyret","genericName":"GLECAPREVIR","slug":"glecaprevir","indication":"Chronic hepatitis C","status":"marketed"},{"name":"OBV/PTV/r","genericName":"OBV/PTV/r","slug":"obv-ptv-r","indication":"Chronic hepatitis C virus infection","status":"phase_3"},{"name":"Paritaprevir/ritonavir/ombitasvir","genericName":"Paritaprevir/ritonavir/ombitasvir","slug":"paritaprevir-ritonavir-ombitasvir","indication":"Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)","status":"phase_3"},{"name":"Placebo for ABT-450/r/ABT-267","genericName":"Placebo for ABT-450/r/ABT-267","slug":"placebo-for-abt-450-r-abt-267","indication":"Hepatitis C virus infection (control arm in phase 3 trials)","status":"phase_3"},{"name":"Placebo for Ribavirin","genericName":"Placebo for Ribavirin","slug":"placebo-for-ribavirin","indication":"Control arm in Phase 3 clinical trial for Ribavirin (antiviral indication, likely viral hepatitis or respiratory viral infection)","status":"phase_3"},{"name":"Teflaro","genericName":"CEFTAROLINE FOSAMIL","slug":"ceftaroline-fosamil","indication":"Bacterial infection due to Klebsiella pneumoniae","status":"marketed"},{"name":"Viekira Pak (Copackaged)","genericName":"DASABUVIR","slug":"dasabuvir","indication":"Chronic hepatitis C","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":8,"colorKey":"rare","drugs":[{"name":"Bimatoprost (SR)","genericName":"Bimatoprost (SR)","slug":"bimatoprost-sr","indication":"Open-angle glaucoma","status":"phase_3"},{"name":"ABT-SLV187","genericName":"ABT-SLV187","slug":"abt-slv187","indication":"Hypertension","status":"phase_3"},{"name":"Atrasentan high dose group","genericName":"Atrasentan high dose group","slug":"atrasentan-high-dose-group","indication":"Hypertension","status":"phase_2"},{"name":"Atrasentan low dose group","genericName":"Atrasentan low dose group","slug":"atrasentan-low-dose-group","indication":"Pulmonary arterial hypertension","status":"phase_2"},{"name":"Betagan","genericName":"LEVOBUNOLOL","slug":"levobunolol","indication":"Ocular hypertension","status":"marketed"},{"name":"Dicuman","genericName":"dicoumarol","slug":"dicoumarol","indication":"Cerebral embolism","status":"marketed"},{"name":"Sham Bimatoprost SR","genericName":"Sham Bimatoprost SR","slug":"sham-bimatoprost-sr","indication":"Treatment of glaucoma and ocular hypertension","status":"phase_3"},{"name":"Teveten","genericName":"EPROSARTAN","slug":"eprosartan","indication":"Hypertensive disorder","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"metabolic","drugs":[{"name":"Choloxin","genericName":"DEXTROTHYROXINE","slug":"dextrothyroxine","indication":"Hyperlipidemia","status":"marketed"},{"name":"ABBV-951","genericName":"ABBV-951","slug":"abbv-951","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"ABT-288 High Dose","genericName":"ABT-288 High Dose","slug":"abt-288-high-dose","indication":"Type 2 diabetes","status":"phase_2"},{"name":"Ranibizumab Control","genericName":"Ranibizumab Control","slug":"ranibizumab-control","indication":"Age-related macular degeneration (wet/neovascular)","status":"phase_3"},{"name":"Trilipix","genericName":"CHOLINE FENOFIBRATE","slug":"choline-fenofibrate","indication":"Familial hypercholesterolemia - heterozygous","status":"marketed"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"respiratory","drugs":[{"name":"Alocril","genericName":"NEDOCROMIL","slug":"nedocromil","indication":"Allergic conjunctivitis","status":"marketed"},{"name":"ABT-652","genericName":"ABT-652","slug":"abt-652","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"Placebo to dupilumab","genericName":"Placebo to dupilumab","slug":"placebo-to-dupilumab","indication":"Moderate to severe atopic dermatitis","status":"phase_3"},{"name":"Survanta","genericName":"BERACTANT","slug":"beractant","indication":"Respiratory distress syndrome in the newborn","status":"marketed"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"ophthalmology","drugs":[{"name":"REFRESH OPTIVE UD","genericName":"REFRESH OPTIVE UD","slug":"refresh-optive-ud","indication":"Dry eye disease / Keratoconjunctivitis sicca","status":"phase_3"},{"name":"Bimatoprost Sustained Release Implant","genericName":"Bimatoprost Sustained Release Implant","slug":"bimatoprost-sustained-release-implant","indication":"Treatment of glaucoma","status":"phase_2"},{"name":"Dipivefrin","genericName":"dipivefrine","slug":"dipivefrine","indication":"Open-angle glaucoma","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"dermatology","drugs":[{"name":"Viberzi","genericName":"ELUXADOLINE","slug":"eluxadoline","indication":"Irritable bowel syndrome with diarrhea","status":"marketed"}]}],"pipeline":[{"name":"Abrilada","genericName":"Adalimumab-Afzb","slug":"abrilada","phase":"marketed","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.","indications":["Ankylosing spondylitis","Axial spondyloarthritis","Behcet's disease","Crohn's disease","Hidradenitis suppurativa"],"catalyst":""},{"name":"Skyrizi","genericName":"RISANKIZUMAB","slug":"risankizumab","phase":"marketed","mechanism":"Skyrizi works by blocking the interleukin-23 protein, which plays a key role in inflammation and immune response.","indications":["Crohn's disease","Erythrodermic psoriasis","Plaque psoriasis","Psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"Rinvoq","genericName":"upadacitinib","slug":"upadacitinib","phase":"marketed","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways.","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Atopic Dermatitis","Ulcerative Colitis","Crohn’s Disease"],"catalyst":""},{"name":"Vraylar","genericName":"CARIPRAZINE","slug":"cariprazine","phase":"marketed","mechanism":"Vraylar works by selectively blocking the D3 dopamine receptor, which helps regulate mood and behavior.","indications":["Bipolar affective disorder, current episode manic","Mixed bipolar I disorder","Schizophrenia"],"catalyst":""},{"name":"Imbruvica","genericName":"ibrutinib","slug":"ibrutinib","phase":"marketed","mechanism":"Imbruvica works by blocking the activity of a specific enzyme called Bruton's tyrosine kinase (BTK), which is involved in the growth and survival of cancer cells.","indications":["Chronic graft-versus-host disease","Chronic lymphoid leukemia, disease","M  lymphoplasmacytic","Malignant lymphoma - small lymphocytic","Mantle cell lymphoma"],"catalyst":""},{"name":"Venclexta","genericName":"venetoclax","slug":"venetoclax","phase":"marketed","mechanism":"Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein.","indications":["Acute myeloid leukemia, disease","Chronic lymphoid leukemia, disease","Malignant lymphoma - small lymphocytic"],"catalyst":""},{"name":"Ubrelvy","genericName":"UBROGEPANT","slug":"ubrogepant","phase":"marketed","mechanism":"Ubrelvy blocks the action of a molecule called calcitonin gene-related peptide, which is involved in migraine pain.","indications":["Migraine"],"catalyst":""},{"name":"Orilissa","genericName":"ELAGOLIX","slug":"elagolix","phase":"marketed","mechanism":"Orilissa blocks the hormone signals that stimulate the growth of endometrial tissue.","indications":["Endometriosis"],"catalyst":""},{"name":"Dalvance","genericName":"DALBAVANCIN","slug":"dalbavancin","phase":"marketed","mechanism":"Dalvance works by binding to the bacterial cell wall, disrupting its synthesis and ultimately leading to cell death.","indications":["Bacterial infection of skin","Infection of skin AND/OR subcutaneous tissue","Staphylococcal infection of skin"],"catalyst":""},{"name":"Qulipta","genericName":"ATOGEPANT","slug":"atogepant","phase":"marketed","mechanism":"Qulipta works by blocking the action of a natural chemical called calcitonin gene-related peptide type 1, which is involved in migraine pain.","indications":["Preventive treatment of migraine"],"catalyst":""},{"name":"Humira","genericName":"ADALIMUMAB","slug":"adalimumab","phase":"marketed","mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors.","indications":["Ankylosing spondylitis","Axial spondyloarthritis","Behcet's disease","Crohn's disease","Hidradenitis suppurativa"],"catalyst":""},{"name":"Nimbex","genericName":"Cisatracurium Besylate","slug":"cisatracurium-besylate","phase":"marketed","mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction.","indications":["Tracheal intubation in adults","Tracheal intubation in pediatric patients","Skeletal muscle relaxation during surgery in adults","Skeletal muscle relaxation during surgery in pediatric patients","Mechanical ventilation in the ICU in adults"],"catalyst":""},{"name":"Norvir","genericName":"ritonavir","slug":"ritonavir","phase":"marketed","mechanism":"Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body.","indications":["COVID-19","Chronic hepatitis C","Human immunodeficiency virus infection"],"catalyst":""},{"name":"Actigall","genericName":"URSODIOL","slug":"ursodiol","phase":"marketed","mechanism":"CDGSH iron-sulfur domain-containing protein 1","indications":["Calculus in biliary tract","Cholelithiasis Prevention","Primary biliary cirrhosis"],"catalyst":""},{"name":"Ravaglimab","genericName":"Ravaglimab","slug":"ravaglimab","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-011","genericName":"ABBV-011","slug":"abbv-011","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-1042","genericName":"ABBV-1042","slug":"abbv-1042","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-142","genericName":"ABBV-142","slug":"abbv-142","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-157","genericName":"ABBV-157","slug":"abbv-157","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-181","genericName":"ABBV-181","slug":"abbv-181","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-243","genericName":"ABBV-243","slug":"abbv-243","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-277","genericName":"ABBV-277","slug":"abbv-277","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-291","genericName":"ABBV-291","slug":"abbv-291","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-295","genericName":"ABBV-295","slug":"abbv-295","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-3067","genericName":"ABBV-3067","slug":"abbv-3067","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-319","genericName":"ABBV-319","slug":"abbv-319","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-324","genericName":"ABBV-324","slug":"abbv-324","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-368","genericName":"ABBV-368","slug":"abbv-368","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-400","genericName":"ABBV-400","slug":"abbv-400","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-428","genericName":"ABBV-428","slug":"abbv-428","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-438","genericName":"ABBV-438","slug":"abbv-438","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-444","genericName":"ABBV-444","slug":"abbv-444","phase":"phase_3","mechanism":"ABBV-444 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-driven cancer cell growth.","indications":["Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer"],"catalyst":""},{"name":"ABBV-47D11","genericName":"ABBV-47D11","slug":"abbv-47d11","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-621","genericName":"ABBV-621","slug":"abbv-621","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-637","genericName":"ABBV-637","slug":"abbv-637","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-6628","genericName":"ABBV-6628","slug":"abbv-6628","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-701","genericName":"ABBV-701","slug":"abbv-701","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-711","genericName":"ABBV-711","slug":"abbv-711","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-901","genericName":"ABBV-901","slug":"abbv-901","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-903 Tablet Form 2","genericName":"ABBV-903 Tablet Form 2","slug":"abbv-903-tablet-form-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-932","genericName":"ABBV-932","slug":"abbv-932","phase":"phase_2","mechanism":"ABBV-932 is a bispecific antibody that simultaneously engages CD3 on T cells and a tumor-associated antigen to redirect immune cells to kill cancer cells.","indications":["Solid tumors (specific indications under investigation in phase 2)"],"catalyst":""},{"name":"ABBV-CLS-628","genericName":"ABBV-CLS-628","slug":"abbv-cls-628","phase":"phase_2","mechanism":"ABBV-CLS-628 is a small molecule targeting the S1P1 receptor.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"ABT-333","genericName":"ABT-333","slug":"abt-333","phase":"phase_3","mechanism":"ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1)"],"catalyst":""},{"name":"ABT-414","genericName":"ABT-414","slug":"abt-414","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-530","genericName":"ABT-530","slug":"abt-530","phase":"phase_2","mechanism":"ABT-530 is a selective inhibitor of the chemokine receptor CCR2 that reduces inflammatory monocyte recruitment to sites of inflammation.","indications":["Inflammatory conditions (Phase 2 development)"],"catalyst":""},{"name":"ABT-894","genericName":"ABT-894","slug":"abt-894","phase":"phase_2","mechanism":"ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Relapsing multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"Alocril","genericName":"NEDOCROMIL","slug":"nedocromil","phase":"marketed","mechanism":"G-protein coupled receptor 35","indications":["Allergic conjunctivitis","Asthma","Asthma management","Ocular Itching"],"catalyst":""},{"name":"Alvinol","genericName":"ETHCHLORVYNOL","slug":"ethchlorvynol","phase":"marketed","mechanism":"GABA-A receptor alpha-1/beta-3/gamma-2","indications":["Insomnia","Severe Insomnia"],"catalyst":""},{"name":"Betaprone","genericName":"PROPIOLACTONE","slug":"propiolactone","phase":"marketed","mechanism":"Small molecule","indications":["Antiseptic preparation"],"catalyst":""},{"name":"Bimatoprost (SR)","genericName":"Bimatoprost (SR)","slug":"bimatoprost-sr","phase":"phase_3","mechanism":"Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""},{"name":"Campral","genericName":"ACAMPROSATE","slug":"acamprosate","phase":"marketed","mechanism":"Campral works by modulating the activity of the GABA-A receptor, a key neurotransmitter system involved in regulating alcohol cravings and withdrawal symptoms.","indications":["Alcoholism"],"catalyst":""},{"name":"Ceftaroline Fosamil","genericName":"CEFTAROLINE","slug":"ceftaroline","phase":"marketed","mechanism":"Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins.","indications":["Acute bacterial skin and skin structure infections","Community-acquired bacterial pneumonia"],"catalyst":""},{"name":"Choloxin","genericName":"DEXTROTHYROXINE","slug":"dextrothyroxine","phase":"marketed","mechanism":"Thyroid hormone receptor","indications":["Hyperlipidemia"],"catalyst":""},{"name":"Corticosteroid (CS)","genericName":"Corticosteroid (CS)","slug":"corticosteroid-cs","phase":"marketed","mechanism":"Corticosteroids suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.","indications":["Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)","Allergic and respiratory conditions (e.g., asthma, allergic rhinitis)","Adrenal insufficiency","Certain hematologic malignancies"],"catalyst":""},{"name":"Emrelis","genericName":"TELISOTUZUMAB","slug":"telisotuzumab","phase":"marketed","mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals.","indications":["non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression"],"catalyst":""},{"name":"FOSCARBIDOPA","genericName":"FOSCARBIDOPA","slug":"foscarbidopa","phase":"marketed","mechanism":"Foscarbidopa works by increasing the levels of dopamine in the brain, a neurotransmitter that is often deficient in people with Parkinson's disease.","indications":["Parkinson's disease"],"catalyst":""},{"name":"Lastacaft","genericName":"ALCAFTADINE","slug":"alcaftadine","phase":"marketed","mechanism":"Lastacaft blocks histamine at the H1 receptor to reduce allergic symptoms.","indications":["Allergic conjunctivitis"],"catalyst":""},{"name":"Medrifar","genericName":"MEDRYSONE","slug":"medrysone","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Allergic conjunctivitis","Corneal abrasion","Corneal ulcer","Cyclitis","Herpes zoster keratitis"],"catalyst":""},{"name":"Metabarbital","genericName":"METHARBITAL","slug":"metharbital","phase":"marketed","mechanism":"GABA-A receptor; anion channel","indications":["Epilepsy","Insomnia","Tonic-clonic epilepsy"],"catalyst":""},{"name":"Phenurone","genericName":"PHENACEMIDE","slug":"phenacemide","phase":"marketed","mechanism":"Sodium channel protein type 1 subunit alpha","indications":["Epilepsy","Epilepsy characterized by intractable complex partial seizures"],"catalyst":""},{"name":"Placebo for E2/NETA","genericName":"Placebo for E2/NETA","slug":"placebo-for-e2-neta","phase":"phase_3","mechanism":"This is a placebo control arm with no active pharmacological mechanism.","indications":["Control arm in phase 3 trial for estradiol/norethindrone acetate (E2/NETA) hormone replacement therapy"],"catalyst":""},{"name":"REFRESH OPTIVE UD","genericName":"REFRESH OPTIVE UD","slug":"refresh-optive-ud","phase":"phase_3","mechanism":"REFRESH OPTIVE UD is an artificial tear solution that lubricates and protects the ocular surface to relieve dry eye symptoms.","indications":["Dry eye disease / Keratoconjunctivitis sicca"],"catalyst":""},{"name":"Sanctura","genericName":"TROSPIUM","slug":"trospium","phase":"marketed","mechanism":"Sanctura works by blocking the action of a chemical called acetylcholine at the M3 receptor in the bladder muscle, reducing muscle contractions and urgency.","indications":["Bladder muscle dysfunction - overactive","Increased Urinary Frequency","Urge incontinence of urine","Urgent desire to urinate"],"catalyst":""},{"name":"Viibryd","genericName":"vilazodone","slug":"vilazodone","phase":"marketed","mechanism":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 4, 5-hydroxytryptamine receptor 7","indications":["Major depressive disorder"],"catalyst":""},{"name":"Zemplar","genericName":"PARICALCITOL","slug":"paricalcitol","phase":"marketed","mechanism":"Zemplar works by activating the Vitamin D3 receptor, mimicking the natural effects of Vitamin D to regulate calcium levels and bone health.","indications":["Hyperparathyroidism Secondary to Chronic Renal Failure"],"catalyst":""},{"name":"ABBV-066","genericName":"ABBV-066","slug":"abbv-066","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-075","genericName":"ABBV-075","slug":"abbv-075","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-085","genericName":"ABBV-085","slug":"abbv-085","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-101","genericName":"ABBV-101","slug":"abbv-101","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-1354","genericName":"ABBV-1354","slug":"abbv-1354","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-141","genericName":"ABBV-141","slug":"abbv-141","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-154 Dose Formulation A","genericName":"ABBV-154 Dose Formulation A","slug":"abbv-154-dose-formulation-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-154 Dose Formulation B","genericName":"ABBV-154 Dose Formulation B","slug":"abbv-154-dose-formulation-b","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-155","genericName":"ABBV-155","slug":"abbv-155","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-2222","genericName":"ABBV-2222","slug":"abbv-2222","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-2B04","genericName":"ABBV-2B04","slug":"abbv-2b04","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-321","genericName":"ABBV-321","slug":"abbv-321","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-453","genericName":"ABBV-453","slug":"abbv-453","phase":"phase_1","mechanism":"BTK inhibitor","indications":["Non-Hodgkin lymphoma"],"catalyst":""},{"name":"ABBV-525","genericName":"ABBV-525","slug":"abbv-525","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-547","genericName":"ABBV-547","slug":"abbv-547","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-552","genericName":"ABBV-552","slug":"abbv-552","phase":"phase_2","mechanism":"ABBV-552 is a small molecule inhibitor of the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Moderate to severe multiple sclerosis"],"catalyst":""},{"name":"ABBV-668","genericName":"ABBV-668","slug":"abbv-668","phase":"phase_2","mechanism":"ABBV-668 is a selective, irreversible inhibitor of Bruton's tyrosine kinase (BTK).","indications":["Relapsed or refractory mantle cell lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"ABBV-668 IR","genericName":"ABBV-668 IR","slug":"abbv-668-ir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-706","genericName":"ABBV-706","slug":"abbv-706","phase":"phase_3","mechanism":"ABBV-706 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment.","indications":["Advanced solid tumors (in combination with checkpoint inhibitors)","Non-small cell lung cancer"],"catalyst":""},{"name":"ABBV-722","genericName":"ABBV-722","slug":"abbv-722","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-8736","genericName":"ABBV-8736","slug":"abbv-8736","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-903 Tablet Form 1","genericName":"ABBV-903 Tablet Form 1","slug":"abbv-903-tablet-form-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-916","genericName":"ABBV-916","slug":"abbv-916","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-927","genericName":"ABBV-927","slug":"abbv-927","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-951","genericName":"ABBV-951","slug":"abbv-951","phase":"phase_3","mechanism":"ABBV-951 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"ABBV-969","genericName":"ABBV-969","slug":"abbv-969","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-CLS-579","genericName":"ABBV-CLS-579","slug":"abbv-cls-579","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABBV-CLS-616","genericName":"ABBV-CLS-616","slug":"abbv-cls-616","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-267","genericName":"ABT-267","slug":"abt-267","phase":"phase_3","mechanism":"ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation.","indications":["Diabetic kidney disease","Liver fibrosis / NASH (non-alcoholic steatohepatitis)"],"catalyst":""},{"name":"ABT-288 High Dose","genericName":"ABT-288 High Dose","slug":"abt-288-high-dose","phase":"phase_2","mechanism":"ABT-288 High Dose is a glucagon receptor antagonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"ABT-288 Low Dose","genericName":"ABT-288 Low Dose","slug":"abt-288-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-308","genericName":"ABT-308","slug":"abt-308","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-348","genericName":"ABT-348","slug":"abt-348","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-348 and azacitidine","genericName":"ABT-348 and azacitidine","slug":"abt-348-and-azacitidine","phase":"phase_1","mechanism":"AZA is a hypomethylating agent that targets DNA methyltransferase enzymes.","indications":["Acute myeloid leukemia","Myelodysplastic syndromes"],"catalyst":""},{"name":"ABT-348 and carboplatin","genericName":"ABT-348 and carboplatin","slug":"abt-348-and-carboplatin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-348 and docetaxel","genericName":"ABT-348 and docetaxel","slug":"abt-348-and-docetaxel","phase":"phase_1","mechanism":"Docetaxel is a microtubule inhibitor that works by stabilizing microtubules and preventing cell division.","indications":["Non-small cell lung cancer","Breast cancer","Prostate cancer"],"catalyst":""},{"name":"ABT-354","genericName":"ABT-354","slug":"abt-354","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-450","genericName":"ABT-450","slug":"abt-450","phase":"phase_2","mechanism":"ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus.","indications":["Chronic hepatitis C virus (HCV) infection","HCV genotype 1 infection"],"catalyst":""},{"name":"ABT-450/r/ABT-267","genericName":"ABT-450/r/ABT-267","slug":"abt-450-r-abt-267","phase":"phase_3","mechanism":"ABT-450/r/ABT-267 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor (ABT-450) boosted with ritonavir and an NS5A inhibitor (ABT-267) that blocks viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1)"],"catalyst":""},{"name":"ABT-450/r/ABT-267, ABT-333","genericName":"ABT-450/r/ABT-267, ABT-333","slug":"abt-450-r-abt-267-abt-333","phase":"phase_3","mechanism":"This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1"],"catalyst":""},{"name":"ABT-450/ritonavir","genericName":"ABT-450/ritonavir","slug":"abt-450-ritonavir","phase":"phase_3","mechanism":"ABT-450 is a hepatitis C virus NS3/4A protease inhibitor that blocks viral replication, boosted by ritonavir to increase drug levels.","indications":["Chronic hepatitis C virus infection (genotype 1 and 4)"],"catalyst":""},{"name":"ABT-493","genericName":"ABT-493","slug":"abt-493","phase":"phase_2","mechanism":"ABT-493 is a protease inhibitor.","indications":["Chronic hepatitis C virus infection"],"catalyst":""},{"name":"ABT-493 coformulated with ABT-530","genericName":"ABT-493 coformulated with ABT-530","slug":"abt-493-coformulated-with-abt-530","phase":"phase_3","mechanism":"ABT-493 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication, coformulated with ABT-530 (an NS5A inhibitor) to enhance antiviral activity.","indications":["Chronic hepatitis C virus (HCV) infection, genotype 1-6"],"catalyst":""},{"name":"ABT-493/ABT-530","genericName":"ABT-493/ABT-530","slug":"abt-493-abt-530","phase":"phase_3","mechanism":"ABT-493/ABT-530 is a fixed-dose combination of a hepatitis C virus NS3/4A protease inhibitor and an NS5A inhibitor that blocks viral replication.","indications":["Chronic hepatitis C virus infection (genotypes 1-6)","Hepatitis C in treatment-naïve and treatment-experienced patients","Hepatitis C with compensated cirrhosis"],"catalyst":""},{"name":"ABT-494","genericName":"ABT-494","slug":"abt-494","phase":"phase_2","mechanism":"ABT-494 is a JAK1 inhibitor that selectively blocks Janus kinase 1 signaling to reduce inflammatory cytokine production and immune cell activation.","indications":["Rheumatoid arthritis","Inflammatory bowel disease"],"catalyst":""},{"name":"ABT-652","genericName":"ABT-652","slug":"abt-652","phase":"phase_2","mechanism":"ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"ABT-652 NSAID","genericName":"ABT-652 NSAID","slug":"abt-652-nsaid","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-700","genericName":"ABT-700","slug":"abt-700","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-712","genericName":"ABT-712","slug":"abt-712","phase":"phase_3","mechanism":"ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation.","indications":["Lung cancer with FGFR1 alterations","Other solid tumors with FGFR1 dependency"],"catalyst":""},{"name":"ABT-767","genericName":"ABT-767","slug":"abt-767","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-806","genericName":"ABT-806","slug":"abt-806","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABT-888","genericName":"ABT-888","slug":"abt-888","phase":"phase_2","mechanism":"ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.","indications":["Metastatic breast cancer, triple-negative breast cancer, ovarian cancer"],"catalyst":""},{"name":"ABT-981","genericName":"ABT-981","slug":"abt-981","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ABT-SLV187","genericName":"ABT-SLV187","slug":"abt-slv187","phase":"phase_3","mechanism":"ABT-SLV187 is a selective inhibitor of soluble epoxide hydrolase (sEH) that increases levels of epoxyeicosatrienoic acids (EETs) to reduce inflammation and improve cardiovascular function.","indications":["Hypertension","Chronic kidney disease"],"catalyst":""},{"name":"AGN-151586","genericName":"AGN-151586","slug":"agn-151586","phase":"phase_3","mechanism":"AGN-151586 is a selective androgen receptor modulator (SARM) that activates androgen signaling in a tissue-selective manner.","indications":["Muscle wasting / sarcopenia","Hypogonadism (potential indication)"],"catalyst":""},{"name":"AGN-151597","genericName":"AGN-151597","slug":"agn-151597","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-151607","genericName":"AGN-151607","slug":"agn-151607","phase":"phase_2","mechanism":"AGN-151607 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"AGN-151607-DP","genericName":"AGN-151607-DP","slug":"agn-151607-dp","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-193408 SR","genericName":"AGN-193408 SR","slug":"agn-193408-sr","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGN-231868","genericName":"AGN-231868","slug":"agn-231868","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALIA-1758","genericName":"ALIA-1758","slug":"alia-1758","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Adalimumab, current formulation","genericName":"Adalimumab, current formulation","slug":"adalimumab-current-formulation","phase":"phase_2","mechanism":"Tumor necrosis factor-alpha inhibitor","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ankylosing Spondylitis","Crohn's Disease","Ulcerative Colitis"],"catalyst":""},{"name":"Adalimumab, new formulation","genericName":"Adalimumab, new formulation","slug":"adalimumab-new-formulation","phase":"phase_2","mechanism":"Adalimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ankylosing spondylitis","Crohn's disease","Ulcerative colitis"],"catalyst":""},{"name":"Akineton","genericName":"BIPERIDEN","slug":"biperiden","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M1","indications":["Arteriosclerotic Parkinsonism","Extrapyramidal disease","Parkinson's disease","Parkinsonism","Postencephalitic parkinsonism"],"catalyst":""},{"name":"Aldapsone","genericName":"aldesulfone","slug":"aldesulfone","phase":"marketed","mechanism":"Glucose-6-phosphate 1-dehydrogenase, Dihydropteroate synthase 1","indications":[],"catalyst":""},{"name":"Armour Thyroid","genericName":"Armour Thyroid","slug":"armour-thyroid","phase":"marketed","mechanism":"Armour Thyroid replaces deficient thyroid hormones by providing a combination of T4 (levothyroxine) and T3 (liothyronine) derived from desiccated porcine thyroid tissue.","indications":["Hypothyroidism (primary, secondary, and tertiary)","Myxedema"],"catalyst":""},{"name":"Atrasentan high dose group","genericName":"Atrasentan high dose group","slug":"atrasentan-high-dose-group","phase":"phase_2","mechanism":"Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.","indications":["Hypertension"],"catalyst":""},{"name":"Atrasentan low dose group","genericName":"Atrasentan low dose group","slug":"atrasentan-low-dose-group","phase":"phase_2","mechanism":"Endothelin receptor antagonist","indications":["Pulmonary arterial hypertension"],"catalyst":""},{"name":"BOTOX®/VISTABEL®","genericName":"BOTOX®/VISTABEL®","slug":"botox-vistabel","phase":"marketed","mechanism":"BOTOX is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Moderate to severe glabellar lines (frown lines)","Moderate to severe lateral canthal lines (crow's feet)","Moderate to severe forehead lines","Chronic migraine","Cervical dystonia"],"catalyst":""},{"name":"Betagan","genericName":"LEVOBUNOLOL","slug":"levobunolol","phase":"marketed","mechanism":"Beta-2 adrenergic receptor","indications":["Ocular hypertension","Open-angle glaucoma"],"catalyst":""},{"name":"Bimatoprost Sustained Release Implant","genericName":"Bimatoprost Sustained Release Implant","slug":"bimatoprost-sustained-release-implant","phase":"phase_2","mechanism":"Bimatoprost Sustained Release Implant works by releasing bimatoprost, a prostaglandin analog, to lower intraocular pressure.","indications":["Treatment of glaucoma"],"catalyst":""},{"name":"Bromanautine","genericName":"bromazine","slug":"bromazine","phase":"marketed","mechanism":"Histamine H1 receptor","indications":["Common cold","Cough","Nasal congestion","Nasal discharge"],"catalyst":""},{"name":"Budiglimab","genericName":"Budiglimab","slug":"budiglimab","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CREON","genericName":"LIPASE","slug":"lipase","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"CREON","genericName":"PROTEASE)","slug":"protease","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Cariprazine Flexible Dose","genericName":"Cariprazine Flexible Dose","slug":"cariprazine-flexible-dose","phase":"phase_3","mechanism":"Cariprazine is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat psychiatric disorders.","indications":["Schizophrenia","Bipolar I disorder (acute mania and maintenance treatment)","Major depressive disorder (adjunctive treatment)"],"catalyst":""},{"name":"Celexa","genericName":"CITALOPRAM","slug":"citalopram","phase":"marketed","mechanism":"Celexa works by blocking the reabsorption of serotonin in the brain, allowing more of this neurotransmitter to be available for communication between nerve cells.","indications":["Depressive disorder","Generalized anxiety disorder","Major depressive disorder"],"catalyst":""},{"name":"Dasabuvir mini tablet","genericName":"Dasabuvir mini tablet","slug":"dasabuvir-mini-tablet","phase":"phase_2","mechanism":"NS5A replication complex inhibitor","indications":["Chronic hepatitis C"],"catalyst":""},{"name":"Dicuman","genericName":"dicoumarol","slug":"dicoumarol","phase":"marketed","mechanism":"NAD(P)H dehydrogenase [quinone] 1","indications":["Cerebral embolism","Myocardial infarction","Prevention of Cerebral Thrombosis","Thromboembolic disorder","Thrombosis"],"catalyst":""},{"name":"Dipivefrin","genericName":"dipivefrine","slug":"dipivefrine","phase":"marketed","mechanism":"Alpha-2A adrenergic receptor","indications":["Open-angle glaucoma"],"catalyst":""},{"name":"Elestat","genericName":"EPINASTINE","slug":"epinastine","phase":"marketed","mechanism":"Elestat works by binding to the histamine H1 receptor, blocking the action of histamine and reducing allergic symptoms.","indications":["Prevention of itching due to allergic conjunctivitis"],"catalyst":""},{"name":"Enablex","genericName":"DARIFENACIN","slug":"darifenacin","phase":"marketed","mechanism":"Enablex works by blocking the action of a chemical called acetylcholine on the bladder muscle, which helps to relax the muscle and improve bladder control.","indications":["Bladder muscle dysfunction - overactive","Increased Urinary Frequency","Urge incontinence of urine","Urgent desire to urinate"],"catalyst":""},{"name":"FOSLEVODOPA","genericName":"FOSLEVODOPA","slug":"foslevodopa","phase":"marketed","mechanism":"Foslevodopa works by increasing the levels of levodopa in the brain, which helps to alleviate symptoms of Parkinson's disease.","indications":["Motor fluctuations in advanced Parkinson’s disease"],"catalyst":""},{"name":"Fetzima","genericName":"LEVOMILNACIPRAN","slug":"levomilnacipran","phase":"marketed","mechanism":"Fetzima works by blocking the reabsorption of serotonin and norepinephrine in the brain, allowing more of these neurotransmitters to be available for communication between brain cells.","indications":["Major depressive disorder"],"catalyst":""},{"name":"Fml","genericName":"FLUOROMETHOLONE","slug":"fluorometholone","phase":"marketed","mechanism":"Glucocorticoid receptor","indications":["Steroid-responsive ocular inflammation"],"catalyst":""},{"name":"Fumaderm","genericName":"Fumaderm","slug":"fumaderm","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HEXOCYCLIUM","genericName":"HEXOCYCLIUM","slug":"hexocyclium","phase":"marketed","mechanism":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","indications":[],"catalyst":""},{"name":"Kaletra","genericName":"LOPINAVIR","slug":"lopinavir","phase":"marketed","mechanism":"Kaletra blocks the protease enzyme, preventing the HIV virus from replicating.","indications":["HIV-1 Infection Treatment"],"catalyst":""},{"name":"Kybella","genericName":"DEOXYCHOLIC ACID","slug":"deoxycholic-acid","phase":"marketed","mechanism":"Kybella works by targeting and destroying excess fat cells through a process that involves disrupting the cell membrane.","indications":["Excess subcutaneous fat"],"catalyst":""},{"name":"Leuprolide Acetate (LA)","genericName":"Leuprolide Acetate (LA)","slug":"leuprolide-acetate-la","phase":"phase_3","mechanism":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids","Precocious puberty","Breast cancer (premenopausal women)"],"catalyst":""},{"name":"Leuprolide Acetate 3 Month Depot","genericName":"Leuprolide Acetate 3 Month Depot","slug":"leuprolide-acetate-3-month-depot","phase":"phase_3","mechanism":"Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.","indications":["Advanced prostate cancer","Endometriosis","Uterine fibroids (leiomyomata)","Central precocious puberty"],"catalyst":""},{"name":"Levodopa-carbidopa intestinal gel","genericName":"Levodopa-carbidopa intestinal gel","slug":"levodopa-carbidopa-intestinal-gel","phase":"phase_3","mechanism":"Levodopa-carbidopa intestinal gel delivers dopamine precursor (levodopa) directly to the small intestine via continuous infusion, bypassing gastric degradation and improving motor symptom control in advanced Parkinson's disease.","indications":["Advanced Parkinson's disease with motor fluctuations inadequately controlled by oral levodopa-carbidopa"],"catalyst":""},{"name":"Levodopa/Carbidopa (LD/CD)","genericName":"Levodopa/Carbidopa (LD/CD)","slug":"levodopa-carbidopa-ld-cd","phase":"phase_3","mechanism":"Levodopa is converted to dopamine in the brain to replace deficient neurotransmitter levels, while carbidopa inhibits premature conversion in the periphery, allowing more levodopa to reach the central nervous system.","indications":["Parkinson's disease","Restless legs syndrome (off-label use)"],"catalyst":""},{"name":"Linzess","genericName":"LINACLOTIDE","slug":"linaclotide","phase":"marketed","mechanism":"Linzess works by activating the heat-stable enterotoxin receptor to increase fluid secretion in the intestines.","indications":["Chronic idiopathic constipation","Irritable bowel syndrome","Irritable bowel syndrome characterized by constipation"],"catalyst":""},{"name":"Lubricating Eye Drops","genericName":"Lubricating Eye Drops","slug":"lubricating-eye-drops","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Matching Placebo for Upadacitinib","genericName":"Matching Placebo for Upadacitinib","slug":"matching-placebo-for-upadacitinib","phase":"phase_3","mechanism":"This is a placebo control formulation with no active pharmaceutical ingredient, used as a comparator in clinical trials.","indications":[],"catalyst":""},{"name":"Mavyret","genericName":"GLECAPREVIR","slug":"glecaprevir","phase":"marketed","mechanism":"Mavyret works by blocking the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating.","indications":["Chronic hepatitis C","Compensated cirrhosis"],"catalyst":""},{"name":"Mirvetuximab soravtansine plus Bevacizumab","genericName":"Mirvetuximab soravtansine plus Bevacizumab","slug":"mirvetuximab-soravtansine-plus-bevacizumab","phase":"phase_3","mechanism":"Mirvetuximab soravtansine targets folate receptor alpha on cancer cells to deliver a cytotoxic payload, while bevacizumab blocks VEGF to inhibit tumor angiogenesis.","indications":["Platinum-resistant ovarian cancer (folate receptor alpha positive)","Recurrent ovarian cancer"],"catalyst":""},{"name":"Mivacron","genericName":"MIVACURIUM","slug":"mivacurium","phase":"marketed","mechanism":"Acetylcholine receptor","indications":["General anesthesia","Muscle relaxation, function","Skeletal Muscle Relaxation for Endotracheal Intubation"],"catalyst":""},{"name":"Namenda","genericName":"MEMANTINE","slug":"memantine","phase":"marketed","mechanism":"Namenda works by blocking the action of glutamate at the NMDA receptor, reducing excessive neural activity associated with Alzheimer's disease.","indications":["Moderate to Severe Alzheimer's Type Dementia"],"catalyst":""},{"name":"Nimbex","genericName":"CISATRACURIUM","slug":"cisatracurium","phase":"marketed","mechanism":"Nimbex works by blocking the action of acetylcholine at the neuromuscular junction, preventing muscle contraction.","indications":["General anesthesia","Muscle relaxation, function","Skeletal Muscle Relaxation for Endotracheal Intubation"],"catalyst":""},{"name":"OBV/PTV/r","genericName":"OBV/PTV/r","slug":"obv-ptv-r","phase":"phase_3","mechanism":"Ombitasvir/paritaprevir/ritonavir is a combination of a protease inhibitor and a non-nucleoside NS5A inhibitor used to treat hepatitis C virus infection.","indications":["Chronic hepatitis C virus infection","Genotype 1, 2, 4, 5, or 6 infection"],"catalyst":""},{"name":"Open-label Adalimumab","genericName":"Open-label Adalimumab","slug":"open-label-adalimumab","phase":"phase_3","mechanism":"Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Ankylosing spondylitis","Psoriatic arthritis"],"catalyst":""},{"name":"Optimized antiparkinsonian treatment","genericName":"Optimized antiparkinsonian treatment","slug":"optimized-antiparkinsonian-treatment","phase":"phase_3","mechanism":"This is a descriptive label for an optimized antiparkinsonian treatment regimen rather than a single drug entity with a defined mechanism.","indications":["Parkinson's disease"],"catalyst":""},{"name":"Osimertinib (Osi)","genericName":"Osimertinib (Osi)","slug":"osimertinib-osi","phase":"marketed","mechanism":"Osimertinib is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations, blocking downstream signaling in cancer cells.","indications":["Metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations (first-line)","Metastatic non-small cell lung cancer with EGFR T790M mutation (second-line, after progression on first- or second-generation EGFR inhibitors)","Adjuvant treatment of stage IB-IIIA EGFR-mutant non-small cell lung cancer after resection"],"catalyst":""},{"name":"PERTZYE","genericName":"PERTZYE","slug":"pertzye","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Paritaprevir/ritonavir/ombitasvir","genericName":"Paritaprevir/ritonavir/ombitasvir","slug":"paritaprevir-ritonavir-ombitasvir","phase":"phase_3","mechanism":"Paritaprevir inhibits hepatitis C virus NS3/4A protease, while ritonavir boosts its levels, and ombitasvir inhibits the NS5A protein, together blocking viral replication.","indications":["Chronic hepatitis C virus infection (genotype 1, 4, 5, 6)"],"catalyst":""},{"name":"Placebo (PBO) oral capsules","genericName":"Placebo (PBO) oral capsules","slug":"placebo-pbo-oral-capsules","phase":"phase_3","mechanism":"Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit.","indications":["Control arm in phase 3 clinical trials (non-therapeutic use)"],"catalyst":""},{"name":"Placebo Methotrexate","genericName":"Placebo Methotrexate","slug":"placebo-methotrexate","phase":"marketed","mechanism":"Methotrexate inhibits dihydrofolate reductase, blocking folate metabolism and reducing DNA synthesis and cell proliferation.","indications":["Rheumatoid arthritis","Psoriasis","Psoriatic arthritis","Ankylosing spondylitis","Various malignancies (acute leukemias, lymphomas, breast cancer)"],"catalyst":""},{"name":"Placebo Upadacitinib","genericName":"Placebo Upadacitinib","slug":"placebo-upadacitinib","phase":"marketed","mechanism":"Upadacitinib is a JAK1-selective inhibitor that suppresses inflammatory signaling pathways by blocking Janus kinase 1.","indications":["Rheumatoid arthritis","Atopic dermatitis","Ulcerative colitis","Crohn's disease"],"catalyst":""},{"name":"Placebo for ABBV-951","genericName":"Placebo for ABBV-951","slug":"placebo-for-abbv-951","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":[],"catalyst":""},{"name":"Placebo for ABT-333","genericName":"Placebo for ABT-333","slug":"placebo-for-abt-333","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":[],"catalyst":""},{"name":"Placebo for ABT-414","genericName":"Placebo for ABT-414","slug":"placebo-for-abt-414","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo for ABT-450/r/ABT-267","genericName":"Placebo for ABT-450/r/ABT-267","slug":"placebo-for-abt-450-r-abt-267","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":["Hepatitis C virus infection (control arm in phase 3 trials)"],"catalyst":""},{"name":"Placebo for ABT-493/ABT-530","genericName":"Placebo for ABT-493/ABT-530","slug":"placebo-for-abt-493-abt-530","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo for Atogepant","genericName":"Placebo for Atogepant","slug":"placebo-for-atogepant","phase":"phase_3","mechanism":"This is a placebo control with no active pharmacological mechanism.","indications":["Control arm in atogepant clinical trials for migraine prevention"],"catalyst":""},{"name":"Placebo for Elagolix","genericName":"Placebo for Elagolix","slug":"placebo-for-elagolix","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 clinical trials for Elagolix"],"catalyst":""},{"name":"Placebo for Estradiol/Norethindrone Acetate","genericName":"Placebo for Estradiol/Norethindrone Acetate","slug":"placebo-for-estradiol-norethindrone-acetate","phase":"phase_3","mechanism":"This is a placebo control formulation containing inert ingredients with no active pharmacological effect, used as a comparator in clinical trials of Estradiol/Norethindrone Acetate.","indications":["Control arm in clinical trials of Estradiol/Norethindrone Acetate for menopausal symptom management"],"catalyst":""},{"name":"Placebo for Linaclotide","genericName":"Placebo for Linaclotide","slug":"placebo-for-linaclotide","phase":"phase_3","mechanism":"This is a placebo control, containing no active pharmaceutical ingredient and therefore has no mechanistic action.","indications":["Control arm in linaclotide clinical trials (Phase 3)"],"catalyst":""},{"name":"Placebo for Navitoclax","genericName":"Placebo for Navitoclax","slug":"placebo-for-navitoclax","phase":"phase_3","mechanism":"Navitoclax is an inhibitor of BCL-2 family proteins.","indications":["Chronic lymphocytic leukemia (CLL)"],"catalyst":""},{"name":"Placebo for Ribavirin","genericName":"Placebo for Ribavirin","slug":"placebo-for-ribavirin","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trial for Ribavirin (antiviral indication, likely viral hepatitis or respiratory viral infection)"],"catalyst":""},{"name":"Placebo for Risankizumab SC","genericName":"Placebo for Risankizumab SC","slug":"placebo-for-risankizumab-sc","phase":"phase_3","mechanism":"This is a placebo control used in clinical trials to compare against risankizumab, an IL-23 inhibitor.","indications":["Control arm in risankizumab phase 3 trials (likely psoriasis, Crohn's disease, or ulcerative colitis based on risankizumab's development program)"],"catalyst":""},{"name":"Placebo for Topiramate","genericName":"Placebo for Topiramate","slug":"placebo-for-topiramate","phase":"phase_3","mechanism":"Placebo does not have a pharmacological effect.","indications":["Control for Topiramate efficacy in clinical trials"],"catalyst":""},{"name":"Placebo for Ubrogepant","genericName":"Placebo for Ubrogepant","slug":"placebo-for-ubrogepant","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Control arm in Phase 3 clinical trials for ubrogepant (acute migraine treatment)"],"catalyst":""},{"name":"Placebo for Upadacitinib","genericName":"Placebo for Upadacitinib","slug":"placebo-for-upadacitinib","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 clinical trials for upadacitinib indications (e.g., rheumatoid arthritis, atopic dermatitis, ulcerative colitis)"],"catalyst":""},{"name":"Placebo for venetoclax","genericName":"Placebo for venetoclax","slug":"placebo-for-venetoclax","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in phase 3 clinical trial for venetoclax"],"catalyst":""},{"name":"Placebo to dupilumab","genericName":"Placebo to dupilumab","slug":"placebo-to-dupilumab","phase":"phase_3","mechanism":"Dupilumab is a monoclonal antibody that blocks the action of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key cytokines involved in the inflammatory process.","indications":["Moderate to severe atopic dermatitis","Asthma with an eosinophilic phenotype","Chronic rhinosinusitis with nasal polyps"],"catalyst":""},{"name":"Placebo to upadacitinib","genericName":"Placebo to upadacitinib","slug":"placebo-to-upadacitinib","phase":"phase_3","mechanism":"This is a placebo control arm in a clinical trial; it contains no active drug and serves as a comparator to upadacitinib's JAK inhibition effects.","indications":[],"catalyst":""},{"name":"Placebo to veliparib","genericName":"Placebo to veliparib","slug":"placebo-to-veliparib","phase":"phase_3","mechanism":"Veliparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair and causing cancer cell death.","indications":["Metastatic breast cancer (in combination with chemotherapy)","Ovarian cancer","BRCA-mutated cancers"],"catalyst":""},{"name":"Placebo-Matching Atogepant","genericName":"Placebo-Matching Atogepant","slug":"placebo-matching-atogepant","phase":"phase_3","mechanism":"Atogepant is a calcitonin gene-related peptide (CGRP) receptor antagonist that blocks CGRP signaling to prevent migraine.","indications":["Migraine prevention in adults"],"catalyst":""},{"name":"Ranibizumab Control","genericName":"Ranibizumab Control","slug":"ranibizumab-control","phase":"phase_3","mechanism":"Ranibizumab is a monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), reducing abnormal blood vessel growth and vascular permeability in the eye.","indications":["Age-related macular degeneration (wet/neovascular)","Diabetic macular edema","Retinal vein occlusion","Diabetic retinopathy"],"catalyst":""},{"name":"Rapaflo","genericName":"SILODOSIN","slug":"silodosin","phase":"marketed","mechanism":"Silodosin blocks alpha-1 adrenoreceptors in the prostate and bladder, causing smooth muscle relaxation and improving urine flow.","indications":["Treatment of BPH"],"catalyst":""},{"name":"Sham Bimatoprost SR","genericName":"Sham Bimatoprost SR","slug":"sham-bimatoprost-sr","phase":"phase_3","mechanism":"Sham Bimatoprost SR is a prostaglandin analog that mimics the action of prostaglandin F2-alpha.","indications":["Treatment of glaucoma and ocular hypertension"],"catalyst":""},{"name":"Survanta","genericName":"BERACTANT","slug":"beractant","phase":"marketed","mechanism":"","indications":["Respiratory distress syndrome in the newborn"],"catalyst":""},{"name":"Teflaro","genericName":"CEFTAROLINE FOSAMIL","slug":"ceftaroline-fosamil","phase":"marketed","mechanism":"Teflaro works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.","indications":["Bacterial infection due to Klebsiella pneumoniae","Haemophilus influenzae pneumonia","Infection due to Escherichia coli","Infection due to Staphylococcus aureus","Pneumococcal pneumonia"],"catalyst":""},{"name":"Teveten","genericName":"EPROSARTAN","slug":"eprosartan","phase":"marketed","mechanism":"Type-1 angiotensin II receptor","indications":["Hypertensive disorder"],"catalyst":""},{"name":"Topical corticosteroids (TCS)","genericName":"Topical corticosteroids (TCS)","slug":"topical-corticosteroids-tcs","phase":"phase_3","mechanism":"Topical corticosteroids suppress local immune and inflammatory responses by binding to glucocorticoid receptors in skin cells, reducing inflammation, itching, and redness.","indications":["Inflammatory skin conditions including atopic dermatitis, psoriasis, eczema, and contact dermatitis","Pruritus and other dermatological inflammatory disorders"],"catalyst":""},{"name":"Trilipix","genericName":"CHOLINE FENOFIBRATE","slug":"choline-fenofibrate","phase":"marketed","mechanism":"Fatty acid-binding protein, intestinal","indications":["Familial hypercholesterolemia - heterozygous","Hypercholesterolemia","Hyperlipidemia","Hypertriglyceridemia","Hypoalphalipoproteinemia"],"catalyst":""},{"name":"Upadacitinib (ABT-494)","genericName":"Upadacitinib (ABT-494)","slug":"upadacitinib-abt-494","phase":"phase_3","mechanism":"Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response.","indications":["Rheumatoid arthritis","Psoriatic arthritis","Ulcerative colitis"],"catalyst":""},{"name":"Viberzi","genericName":"ELUXADOLINE","slug":"eluxadoline","phase":"marketed","mechanism":"Viberzi works by activating the mu-opioid receptor in the gut to slow down bowel movements and reduce diarrhea.","indications":["Irritable bowel syndrome with diarrhea"],"catalyst":""},{"name":"Viekira Pak (Copackaged)","genericName":"DASABUVIR","slug":"dasabuvir","phase":"marketed","mechanism":"Protein cereblon","indications":["Chronic hepatitis C"],"catalyst":""},{"name":"modified FOLFIRINOX","genericName":"modified FOLFIRINOX","slug":"modified-folfirinox","phase":"phase_3","mechanism":"Modified FOLFIRINOX is a chemotherapy regimen that combines four drugs to target rapidly dividing cancer cells.","indications":["Metastatic pancreatic cancer"],"catalyst":""},{"name":"placebo for risankizumab","genericName":"placebo for risankizumab","slug":"placebo-for-risankizumab","phase":"marketed","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.","indications":[],"catalyst":""},{"name":"placebo for rizankizumab","genericName":"placebo for rizankizumab","slug":"placebo-for-rizankizumab","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"risankizumab IV","genericName":"risankizumab IV","slug":"risankizumab-iv","phase":"phase_3","mechanism":"Risankizumab is a humanized monoclonal antibody that selectively binds to and blocks the interleukin-23 (IL-23) p19 subunit.","indications":["Moderate to severe plaque psoriasis","Active psoriatic arthritis","Moderate to severe Crohn's disease"],"catalyst":""},{"name":"risankizumab SC","genericName":"risankizumab SC","slug":"risankizumab-sc","phase":"phase_3","mechanism":"Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.","indications":["Moderate to severe plaque psoriasis","Crohn's disease","Ulcerative colitis"],"catalyst":""}],"recentEvents":[{"date":"2023-02-02","type":"earnings","headline":"AbbVie Reports Fourth-Quarter and Full-Year 2022 Results","summary":"AbbVie reported its fourth-quarter and full-year 2022 results, with net revenues of $14.5 billion and adjusted diluted earnings per share of $3.79.","drugName":"","sentiment":"neutral"},{"date":"2022-06-01","type":"deal","headline":"AbbVie to Acquire Teneobio for $2.5 Billion","summary":"AbbVie announced its intention to acquire Teneobio, a biotechnology company focused on developing novel antibody-based therapies, for $2.5 billion.","drugName":"","sentiment":"positive"},{"date":"2021-03-05","type":"regulatory","headline":"FDA Approves AbbVie's Rinvoq for Moderate to Severe Atopic Dermatitis","summary":"The FDA approved AbbVie's Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQa2Nqeko0dEJ2N01TbmRhUC1QaFlKOUE0RFhFNGFTYmFZNFNJN0lRV3p4N3BmNEEzX2pSeU8xY3ZwMGFMczB0WDBSMnZyaWtLT0ZsOE5HS05tY1NGeGNVcnZfT3Z0WEN0enBfUUI3cm4wNnZoRlFwd0QtM0lsV0NkNi0zb3QxX0RkZWhqUFJYMlcyVzE5MUt0NlVQZEVUaHZPeFRvRFdfOWRBT1ZHRmxEQm5ucnV0TjBrMWVKU3ZvWTdYT1JIcldEQ1FGc2RyamNtZnc?oc=5","date":"2026-04-06","type":"pipeline","source":"24/7 Wall St.","summary":"High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout - 24/7 Wall St.","headline":"High Yield vs. Sustainable Growth: Why AbbVie's Dividend Beats Pfizer's Despite the Lower Payout - 24/7 Wall St.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQNzhTU3NtQzhaRUVraFFIUDZzMFA1SU1ENUU4dEFEanNmaDRBNmE5WEY2TndsTkF6VFhsMGlKUlU0emxhbG1KcnJrQzYtVzA0MV9mS2lnQy1pcUl2blc2WHk4LXpMeGV2R1RTa0pZSUxMQmJOTzh6SFFqRzZNZ192cUtka1dqZw?oc=5","date":"2026-04-05","type":"pipeline","source":"TheStreet Pro","summary":"Clipping a 12% Coupon on a Big Pharma Name - TheStreet Pro","headline":"Clipping a 12% Coupon on a Big Pharma Name","sentiment":"neutral"},{"date":"2026-04-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPYlJEWnpCamFsUXZaeHBRbDg5dU0yNkJ5a2RRVGxYMlZaQ0FfOTBqYWJPUVAzRVluc25FdjFyVm5BbWxTd3Rad2UxZGZ6UE1ZdTRMS3E2dTNOdzdJRDd2NEFoQlNMcEdHamFBQXJhVHh5LVFXc3p6eklTSlp5akx0ME9QMnozM3RvZ0FQYjhGSFloTXJyb0lFdmUwbUc?oc=5","date":"2026-03-24","type":"deal","source":"Investing News Network","summary":"AbbVie Named Official Pharmaceutical Partner of Major League Baseball - Investing News Network","headline":"AbbVie Named Official Pharmaceutical Partner of Major League Baseball","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPYzJEa0JvNGYzbVpOQ3JHWVNoZVVwWjgxQmhtQ0liY0NZM2pqcVRSbFdJRTQwQVZSSmpHMjNuRzJwVERiQzI4N1JuVTR3dVhzR25lclcxeUhwMHZXc3plejlRUjJkcFhmalpVWW5TRDFabnNIVm4wQkhqSFpack1ucWF1SQ?oc=5","date":"2026-03-17","type":"pipeline","source":"Yahoo Finance","summary":"AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock - Yahoo Finance","headline":"AbbVie Inc. (ABBV): Billionaire Ken Fisher Admires This Pharma Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOZ3F1RjRIQUJBMEtTdHFzNVRPVDJIQWJ3RmZ5QzN1Sml3VkFTSUxySVI0Wl9IYXZzdjE5MUxKbjcweFpqTm8xNnhjZlk2NndubGt2elh5V2F6RGVoNmpmQTR4ajBMYzlSZi1uNVg1X04wa2Z2RmhZQkdkSlRvTFJfaTRKcXlnSVlGLWJSSTRael91c01uSEdaeA?oc=5","date":"2026-03-04","type":"deal","source":"The Motley Fool","summary":"AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell - The Motley Fool","headline":"AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOc0pLcnZFVU9uTjZjYzhLMjlfN2Z4R2stNy1VbkhjUXdkS1d6RW1vclVBSS0yOFVZeDgxOFlfZFVWUzJDZ3Y3ZmZnYndEZUc1Q3BXUUI4YzJJZlFid2ptSWloUDRWdy1wcmZmRFlGNlVsOUVjV3p6SThwUExFcGE0Y2ZEeTlqbkZZOW80Yi1maXZ6LWNYZEVqTw?oc=5","date":"2026-02-24","type":"pipeline","source":"The Motley Fool","summary":"This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income - The Motley Fool","headline":"This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQN3BnMkNtdUhwS3ZZX2dBbE5HNVgzQXAzOV9zQmhDMTA3YUZmbTJ3QmV6ckRxWmJ4aTE1aUFqTHdoV01peWh6OHlmS1pIcnUtUGhDWU1wV3VCenp1Qjlia1ZBbnR5NHRsYWVibUxRUjVyVWlKY3NLU1NWc0JmT0tYWkMzZnlnaVFmSjc1a0pETHVvYnBQZXEzM2d0N0U2aTFfSndieGJlLVRrWVpBREhUcHdXVUwzQzJJeVJybGtvWWlGNDY2V2QxR2hteklsTlh1djl2Wk1xUW9fVWxJYk0tbVdtb2NTU0NZS3hPdjVsSm1uYkZCSzRRYUVB?oc=5","date":"2026-02-23","type":"pipeline","source":"AbbVie News Center","summary":"AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States - AbbVie News Center","headline":"AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the U","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOcjVURXROa0dpbWhSdEJUSDNlcEpKdkxOaUFyd3N6cUY1TjJEdHFhdzRTcFl4NEN6RXppSXA0THlZaTFnQlAwMjFOVHNlNGtqajVrdWJjU3VLU25POGtRdkxQUW9KMzVxMTZzd2lIa2pjZmNIUENsbEdZQ3V4WTg2UEF4Yw?oc=5","date":"2026-01-10","type":"pipeline","source":"Yahoo Finance","summary":"AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research - Yahoo Finance","headline":"AbbVie Inc. (ABBV) Gets Downgraded to Peer Perform From Outperform by Wolfe Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQUkVPV3E1eWh0ekxxbENpNEhlMDRPUFBKbnRLMlpaSXNISFpyQzJwMlBkQWRFM0liRGo2QzRMcENGa0RuMmNkSFI5akNTQUQwU3hrSW85RzA0Zm1sRUJFYVVYVHVDOVhUUFQ4a2xTSGRFeFp2a19kdnlLVUZVZExyNVBveXJoVjBUYkg1X0ZmMlRuOHZDanhvUUF4dndxdW9Gbnp6cHBZakpIMnpSWC10WlVsLXc4dEpNcFZsSjRKWGFQOWdnUi14TQ?oc=5","date":"2026-01-07","type":"deal","source":"reuters.com","summary":"AbbVie denies media reports of talks to buy Revolution Medicines - reuters.com","headline":"AbbVie denies media reports of talks to buy Revolution Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE9nSXZGMGxZTWJjS195Y0lwSHExenNtVEFXd25YcndBOWJnR2RNN1dSQklUX3I1Vm4xaEJ0QUtDRXF3cS05dmt4X190Rl9tUFA4NEJQaXBqUVRJbU5fNmtfTjUxOUtTVnJYTlk3V1ZmLThoSDJMaFpuLWlR?oc=5","date":"2025-12-23","type":"pipeline","source":"Yahoo Finance","summary":"ABBV vs. AZN: Which Pharma Stock is the Better Investment Now? - Yahoo Finance","headline":"ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNTW9nNjUtSmpObHUzSHBHYU5xV0ZMNTBrMERCSDNlQ1FJc0FBbnAzd0ZGVFp4bzhWamZBVXh1NEt4TnZOV1pzTlYzWmVGaEVwYWVRamdEOWQtVnUtaWU2bmc3Z3pjSE1aVWhTRXZiM2J4bFN1YnF2S2ZqZFFEYjFpdXJDWTdJTEY0MkV3ei1aVUZXaDRnMVAyYVFrbFFKbXFRMXJsdkozeVI1TEM2QUhySGRnNllxQmMwMWR2aXlWUEF0d1N6Z3c?oc=5","date":"2025-12-17","type":"deal","source":"reuters.com","summary":"AbbVie, several other pharma companies near MFN deal with Trump, sources say - reuters.com","headline":"AbbVie, several other pharma companies near MFN deal with Trump, sources say","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQT0hEZ3lzTWx3U01ibl85SGlsck9yRVYzSzdXaTNaMnc4bmFlS1lZc3M3TWxvVmVROWpXOVhMbHJnTkMzamRUNzZ4MWJsNldxVkdQQTdtM3RReDdxTy15SWVGeTJPSmdHa28tSVhfWWFOcklQa1VJSjJ1VzJvNGoyQmFRbVBkYkhJUU1tU2otWEEwR3JyVkRaMTVSRm9jZ3JLVFZFVHlNWnUyalV2aGJ1ejN2RmhQSkMybzFrU2h6Y2RWTkoybFQ0dkZBd04?oc=5","date":"2025-09-29","type":"pipeline","source":"AbbVie News Center","summary":"AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility - AbbVie News Center","headline":"AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility","sentiment":"neutral"}],"patents":[{"drugName":"Humira","drugSlug":"adalimumab","patentNumber":"","type":"Patent Cliff","expiryDate":"2023-06-01","territory":"US","annualRevenue":19800000000},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"8476284*PED","type":"Compound","expiryDate":"2027-06-28","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"8703780*PED","type":"Compound","expiryDate":"2027-06-28","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"8952015*PED","type":"Compound","expiryDate":"2027-06-28","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"8563563*PED","type":"Compound","expiryDate":"2027-10-26","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"8754090","type":"Method of Use","expiryDate":"2031-06-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9814721","type":"Method of Use","expiryDate":"2031-06-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10653696","type":"Method of Use","expiryDate":"2031-06-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9125889*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10004746*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9801883*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9801881*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"8999999*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10016435*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10751342*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"8754090*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9814721*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10653696*PED","type":"Compound","expiryDate":"2031-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10752634","type":"Formulation","expiryDate":"2033-06-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9713617","type":"Formulation","expiryDate":"2033-06-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10294231","type":"Formulation","expiryDate":"2033-06-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10294232","type":"Formulation","expiryDate":"2033-06-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9540382","type":"Method of Use","expiryDate":"2033-08-18","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9713617*PED","type":"Compound","expiryDate":"2033-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10294232*PED","type":"Compound","expiryDate":"2033-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10294231*PED","type":"Compound","expiryDate":"2033-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10752634*PED","type":"Compound","expiryDate":"2033-12-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9540382*PED","type":"Compound","expiryDate":"2034-02-18","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10463668*PED","type":"Compound","expiryDate":"2035-04-24","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10695350*PED","type":"Compound","expiryDate":"2035-04-24","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10010507","type":"Formulation","expiryDate":"2036-03-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10213386","type":"Formulation","expiryDate":"2036-03-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9655857","type":"Formulation","expiryDate":"2036-03-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10828259","type":"Formulation","expiryDate":"2036-03-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"9655857*PED","type":"Compound","expiryDate":"2036-09-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10010507*PED","type":"Compound","expiryDate":"2036-09-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10213386*PED","type":"Compound","expiryDate":"2036-09-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Imbruvica","drugSlug":"ibrutinib","patentNumber":"10828259*PED","type":"Compound","expiryDate":"2036-09-03","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10550126","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11512092","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11365198","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11773106","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11976077","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11524964","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11795175","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11535624","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11535625","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11535626","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11993605","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11993606","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11767326","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10995095","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10597400","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11780848","type":"Method of Use","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"12091415","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10981924","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11198697","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"12103933","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10344036","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10202393","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"12134621","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"12077545","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11787815","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11780847","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"9963459","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"12116373","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10730883","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"12110297","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"10519164","type":"Formulation","expiryDate":"2036-10-17","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11607411","type":"Method of Use","expiryDate":"2038-03-09","territory":"US","annualRevenue":5300000000,"genericFilings":[]},{"drugName":"Rinvoq","drugSlug":"upadacitinib","patentNumber":"11564922","type":"Method of Use","expiryDate":"2038-03-09","territory":"US","annualRevenue":5300000000,"genericFilings":[]}],"drugCount":211,"phaseCounts":{"marketed":67,"discontinued":2,"phase_1":54,"phase_2":31,"phase_3":57},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Pfizer","Merck & Co.","Johnson & Johnson"],"therapeuticFocus":["Immunology","Oncology"],"financials":{"source":"sec_edgar","revenue":61160000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":61160000000,"period":"2025-12-31"},{"value":16618000000,"period":"2025-12-31"},{"value":56334000000,"period":"2024-12-31"},{"value":56334000000,"period":"2024-12-31"},{"value":15102000000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":4226000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":133960000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":210.03,"previousClose":206.37,"fiftyTwoWeekHigh":244.81,"fiftyTwoWeekLow":164.39,"fiftyTwoWeekRange":"164.39 - 244.81","fiftyDayAverage":221.37,"twoHundredDayAverage":216.27,"beta":0.36,"enterpriseValue":428082036736,"forwardPE":13,"priceToBook":-113.53,"priceToSales":6.07,"enterpriseToRevenue":7,"enterpriseToEbitda":14.63,"pegRatio":0.49,"ebitda":29254000640,"ebitdaMargin":47.8,"freeCashflow":18337748992,"operatingCashflow":19029999616,"totalDebt":68400001024,"debtToEquity":0,"currentRatio":0.67,"returnOnAssets":9.8,"returnOnEquity":6225,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":29,"targetMeanPrice":249.14,"targetHighPrice":299,"targetLowPrice":184,"dividendRate":6.92,"payoutRatio":2.77,"fiveYearAvgDividendYield":3.65,"exDividendDate":1776211200,"insiderHeldPercent":0.1,"institutionHeldPercent":76.4,"sharesOutstanding":1768762377,"floatShares":1765057035,"sharesShort":25110220,"shortRatio":3.87,"shortPercentOfFloat":1.4,"epsTrailing":2.37,"epsForward":16.12,"revenuePerShare":34.57,"bookValue":-1.85,"officers":[{"age":55,"name":"Mr. Robert A. Michael CPA","title":"CEO & Chairman of the Board"},{"age":57,"name":"Mr. Scott T. Reents","title":"Executive VP & CFO"},{"age":62,"name":"Dr. Azita  Saleki-Gerhardt Ph.D.","title":"Executive VP & COO"},{"age":53,"name":"Dr. Roopal B. Thakkar M.D.","title":"Executive VP of Research & Development and Chief Scientific Officer"},{"age":56,"name":"Mr. Jeffrey Ryan Stewart","title":"Executive VP & Chief Commercial Officer"},{"age":null,"name":"Ms. Linda  Ray","title":"Senior VP & Chief Information Officer"},{"age":null,"name":"Ms. Elizabeth  Shea","title":"Senior Vice President of Investor Relations"},{"age":50,"name":"Mr. Perry C. Siatis","title":"Executive VP, General Counsel & Secretary"}],"industry":"Drug Manufacturers - General","irWebsite":"","website":"https://www.abbvie.com","phone":"847 932 7900"}}